

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number
WO 2004/077060 A2

- (51) International Patent Classification⁷: **G01N 33/574**
- (21) International Application Number:
PCT/CA2004/000280
- (22) International Filing Date: 26 February 2004 (26.02.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/451,382 27 February 2003 (27.02.2003) US
- (71) Applicant (for all designated States except US): **MOUNT SINAI HOSPITAL** [CA/CA]; 600 University Avenue, Room 970, Toronto, Ontario M5G 1X5 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **DIAMANDIS**, Eleftherios, P. [CA/CA]; 44 Gerrard Street West, Suite 1504, Toronto, Ontario M5G 2K2 (CA). **PETRAKI**, Constantina, D. [GR/GR]; Department of Pathology, Evangelismos Hospital, Phedriodon 109, GR-113 64 Athens (GR).
- (74) Agent: **KURDYDYK**, Linda; McCarthy Tetrault, 66 Wellington Street West, Suite 4700, P.O. Box 48, Toronto Dominion Bank Tower, Toronto Dominion Centre, Toronto, Ontario M5K 1E6 (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/077060 A2

(54) Title: ASSAY FOR DETECTION OF RENAL CELL CARCINOMA

(57) Abstract: Methods for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting kallikrein polypeptides, or polynucleotides encoding the polypeptides in a sample from the subject. The kallikrein polypeptides include kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

TITLE: Assay for Detection of Renal Cell Carcinoma**FIELD OF THE INVENTION**

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating renal cell carcinoma.

BACKGROUND OF THE INVENTION

Kallikreins are a subgroup of secreted serine proteases, encoded by highly conserved and tightly clustered multigene families in humans, rats and mice. The human kallikrein gene family resides on chromosome 19q13.4 and is comprised of 15 members, whose genes are designated as *KLK1* to *KLK15* and the corresponding proteins as hK1 to hK15 (Yousef GM, Diamandis EP., *Endocr Rev* .2001;22:184-204; Yousef GM, Chang A, Scorilas A, et al., *Biochem Biophys Res Commun*. 2000;276:125-133; Diamandis EP, Yousef GM, Clements J, et al. *Clin Chem* .2000;46:1855-1858). Kallikreins are expressed in a wide variety of tissues and are found in many biological fluids (e.g. cerebrospinal fluid, serum, seminal plasma, milk, etc.) where they are predicted to process specific substrates. Kallikreins may participate in cascade reactions similar to those involved in digestion, fibrinolysis, coagulation, wound healing and apoptosis (Yousef GM, Diamandis EP., *Endocr Rev* .2001;22:184-204). Many kallikreins have been found to be differentially expressed in endocrine-related malignancies (Diamandis EP, Yousef GM, *Expert Rev. Mol. Diagn* .2001;1:182-190), including prostate (Barry MJ. Clinical practice, *N Engl J Med* .2001;344:1373-1377; Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al., *Crit Rev Clin Lab Sci* .1998;35:275-368; and Yousef GM, Scorilas A, Jung K, et al., *J Biol Chem* .2001;276:53-61), ovarian (Kim H, Scorilas A, Katsaros D, et al., *Br J Cancer*, 2001;84:643-650; Anisowicz A, Sotiropoulou G, Stenman, et al., *Mol Med* .1996;2:624-636; Tanimoto H, Underwood LJ, Shigemasa K, et al., *Cancer* .1999;86:2074-2082; Magklara A, Scorilas A, Katsaros D, et al., *Clin Cancer Res* .2001;7:806-811; Yousef GM, Kyriakopoulou LG, Scorilas A, et al., *Cancer Res* .2001;61:7811-7818; Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118), breast (Yousef GM, Magklara A, Chang A, et al., *Cancer Res* .2001;61:3425-3431; Yousef GM, Chang A, Diamandis EP; *J Biol Chem* .2000;275:11891-11898; and Yousef GM, Magklara A, Diamandis EP, *Genomics* .2000;69:331-341), and testicular cancer (Luo LY, Rajpert-De Meyts ER, Jung K, et al., 2001;85:220-224). In addition, many kallikrein genes examined thus far are under steroid hormone regulation, implicating a role for kallikreins in endocrine-related tissues (Yousef GM, Diamandis EP., *Endocr Rev.*, 2001;22:184-204). Furthermore, hK6, hK10 and hK11 have been recently identified as novel serological ovarian cancer biomarkers (Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118 Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P., *Clin Biochem*. 2000;33:579-583, and Diamandis EP, Okui A, Mitsui S, et al., *Cancer Res* .2002;62:295-300).

SUMMARY OF THE INVENTION

The present invention seeks to overcome the drawbacks inherent in the prior art and provide sensitive and accurate methods for the detection of renal cell carcinoma. It has been found that one or more kallikrein polypeptides wherein the kallikrein polypeptides are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and polynucleotides encoding the polypeptides, have particular application in the detection of renal cell carcinoma. Thus, the kallikrein markers constitute biomarkers for the diagnosis, monitoring, progression, treatment, and prognosis of renal cell carcinoma, and they may be used as biomarkers before

- 2 -

surgery or after relapse.

In accordance with the methods of the invention, the presence of levels of kallikrein markers in a sample can be assessed, for example by detecting the presence in the sample of (a) polypeptides or polypeptide fragments corresponding to the markers; (b) metabolites which are produced directly or indirectly by polypeptides corresponding to the markers; (c) transcribed nucleic acids or fragments thereof having at least a portion with which the markers are substantially identical; and/or (c) transcribed nucleic acids or fragments thereof, wherein the nucleic acids hybridize with the markers.

In an embodiment, the invention provides a method for detecting one or more kallikrein polypeptides wherein the kallikrein polypeptides are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma in a patient comprising:

- (a) obtaining a sample from a patient;
- (b) detecting or identifying in the sample one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (c) comparing the detected amounts with amounts detected for a standard.

The term "detect" or "detecting" includes assaying, assessing, imaging or otherwise establishing the presence or absence of the target kallikrein polypeptides or polynucleotides encoding the polypeptides, subunits thereof, or combinations of reagent bound targets, and the like, or assaying for, imaging, ascertaining, establishing, or otherwise determining one or more factual characteristics of renal cell carcinoma, metastasis, stage, or similar conditions. The term encompasses diagnostic, prognostic, and monitoring applications. The kallikrein markers can be detected individually, sequentially, or simultaneously.

According to a method involving one or more kallikrein polypeptides the levels in the sample of one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma, are compared with the normal levels of the kallikrein polypeptides, in samples of the same type obtained from controls (e.g. samples from individuals not afflicted with renal cell carcinoma). Significantly different levels in the sample of the kallikrein polypeptides relative to the normal levels in a control is indicative of renal cell carcinoma.

In an embodiment, the invention provides a method for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting in a sample from the subject one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma. The kallikrein markers can be detected using antibodies that bind to the kallikrein markers or parts thereof.

Thus, the invention provides a method of assessing whether a patient is afflicted with or has a pre-disposition for renal cell carcinoma, the method comprising comparing:

- (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and

- 3 -

- 5 (b) normal levels of the kallikrein polypeptides, in samples of the same type obtained from control patients not afflicted with renal cell carcinoma, wherein significantly different levels of the kallikrein polypeptides, relative to the corresponding normal levels of the kallikrein polypeptides, is an indication that the patient is afflicted with renal cell carcinoma.

In an embodiment of a method of assessing whether a patient is afflicted with renal cell carcinoma (e.g. screening, detection of a recurrence, reflex testing), the method comprises comparing:

- 10 (a) levels of one or more, preferably 2 or more, kallikrein polypeptides in a sample from the patient, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels of the kallikrein polypeptides, in a control non-renal cell carcinoma sample.

A significant difference between the levels of the kallikrein polypeptides in the patient sample and the normal levels is an indication that the patient is afflicted with renal cell carcinoma. In an embodiment, the levels of kallikrein markers are significantly higher and are indicative of tumors of high grade, advanced stage disease, and/or lower survival.

15

The invention further relates to a method of assessing the efficacy of a therapy for inhibiting renal cell carcinoma in a patient. This method comprises comparing:

- (a) levels of one or more kallikrein polypeptides in a sample from the patient obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- 20 (b) levels of the kallikrein polypeptides in a second sample obtained from the patient following therapy.

A significant difference between the levels of the kallikrein polypeptides in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting renal cell carcinoma.

25

The "therapy" may be any therapy for treating renal cell carcinoma including but not limited to chemotherapy, immunotherapy, gene therapy, radiation therapy, and surgical removal of tissue. Therefore, the method can be used to evaluate a patient before, during, and after therapy, for example, to evaluate the reduction in tumor burden.

30 In an aspect, the invention provides a method for monitoring the progression of renal cell carcinoma in a patient, the method comprising:

- (a) detecting in a patient sample at a first time point, one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- 35 (b) repeating step (a) at a subsequent point in time; and
- (c) comparing the levels detected in (a) and (b), and therefrom monitoring the progression of renal cell carcinoma in the patient.

In another aspect, the invention provides a method for assessing the aggressiveness or indolence of renal cell carcinoma (e.g. staging), the method comprising comparing:

- 4 -

- (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels of the kallikrein polypeptides in a control sample.

5 A significant difference between the levels in the sample and the normal levels is an indication that the cancer is aggressive or indolent.

The invention provides a method for determining whether renal cell carcinoma has metastasized or is likely to metastasize in the future, the method comprising comparing:

- 10 (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels (or non-metastatic levels) of the kallikrein polypeptides in a control sample.

A significant difference between the levels in the patient sample and the normal levels is an indication that the cancer has metastasized or is likely to metastasize in the future.

15 The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, and a method of selecting an agent for inhibiting renal cell carcinoma in a patient.

The invention further provides a method of inhibiting renal cell carcinoma in a patient comprising:

- 20 (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing levels of one or more kallikrein polypeptides, in each of the aliquots, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma;
- 25 (d) administering to the patient at least one of the test agents which alters the levels of the kallikrein polypeptides in the aliquot containing that test agent, relative to other test agents.

The invention also contemplates a method of assessing the renal cell carcinoma carcinogenic potential of a test compound comprising:

- (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and
- 30 (b) comparing levels of kallikrein polypeptides in each of the aliquots, wherein the polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the kallikrein polypeptides in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses renal cell carcinoma carcinogenic potential.

35 In embodiments of the methods of the invention, two, three, or four kallikrein polypeptides are employed. In preferred embodiments, the kallikrein polypeptides comprise kallikrein 6; kallikrein 6 and kallikrein 10; kallikrein 6 and kallikrein 11; kallikrein 6, kallikrein 10, and kallikrein 11; or kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. In a particular embodiment, the kallikrein polypeptides are selected from the group consisting of kallikrein 6, kallikrein 10, and kallikrein 11.

- 5 -

Other methods of the invention employ one or more polynucleotides capable of hybridizing to polynucleotides encoding kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma. Methods for detecting polynucleotides encoding kallikrein polypeptides can be used to monitor renal cell carcinoma by detecting the nucleic acids.

Thus, the present invention relates to a method for diagnosing and monitoring renal cell carcinoma in a sample from a subject comprising isolating nucleic acids, preferably mRNA, from the sample; and detecting polynucleotides encoding kallikrein polypeptides in the sample, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The presence of different levels of polynucleotides encoding the kallikrein polypeptides, in the sample compared to a standard or control is indicative of disease, disease stage, and/or prognosis, e.g. progression-free and overall survival.

In an embodiment, the invention provides methods for determining the presence or absence of renal cell carcinoma in a subject comprising (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of renal cell carcinoma in the subject. Within certain embodiments, mRNA is detected via polymerase chain reaction using, for example oligonucleotide primers that hybridize to polynucleotides encoding kallikrein polypeptides, or complements of such nucleic acids. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing oligonucleotide probes that hybridize to polynucleotides encoding kallikrein polypeptides, or complements of such nucleic acids.

When using mRNA detection, the method may be carried out by combining isolated mRNA with reagents to convert to cDNA according to standard methods; treating the converted cDNA with amplification reaction reagents (such as cDNA PCR reaction reagents) in a container along with an appropriate mixture of nucleic acid primers; reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of polynucleotides encoding kallikrein polypeptides in the sample. For mRNA the analyzing step may be accomplished using Northern Blot analysis to detect the presence of polynucleotides encoding kallikrein polypeptides. The analysis step may be further accomplished by quantitatively detecting the presence of polynucleotides encoding kallikrein polypeptides in the amplification product, and comparing the quantity of markers detected against a panel of expected values for the known presence or absence of the markers in normal and malignant tissue derived using similar primers.

In embodiments of the invention, one, two, three or four polynucleotides encoding kallikrein polypeptides are employed. In preferred embodiments, the polynucleotides encode kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and kallikrein 6, kallikrein 10 and kallikrein 11.

The invention also provides a diagnostic composition comprising kallikrein polypeptides, or polynucleotides encoding the polypeptides, or agents that bind to the polypeptides or nucleic acids.

In an embodiment, the composition comprises probes that specifically hybridize to polynucleotides

- 6 -

encoding kallikrein polypeptides, or fragments thereof. In another embodiment a composition is provided comprising specific primer pairs capable of amplifying polynucleotides encoding kallikrein polypeptides, using polymerase chain reaction methodologies. In a still further embodiment, the composition comprises agents that bind to kallikrein polypeptides (e.g. antibodies) or fragments thereof. Probes, primers, and agents
5 can be labeled with detectable substances.

In an aspect the invention provides an *in vivo* method comprising administering to a subject agents that have been constructed to target kallikrein polypeptides.

The invention therefore contemplates an *in vivo* method comprising administering to a mammal imaging agents that carry labels for imaging and that bind to kallikrein polypeptides, and then imaging the
10 mammal.

Still further the invention relates to therapeutic applications for renal cell carcinoma employing kallikrein polypeptides and polynucleotides encoding the polypeptides, and/or agents identified using methods of the invention.

The invention also includes kits for carrying out methods of the invention. In an embodiment, the
15 kit is for assessing whether a patient is afflicted with renal cell carcinoma and it comprises reagents for assessing one or more kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

In another aspect the invention relates to a kit for assessing the suitability of each of a plurality of test compounds for inhibiting renal cell carcinoma in a patient. The kit comprises reagents for assessing
20 kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The kit may also comprise a plurality of test agents or compounds.

The invention contemplates a kit for assessing the presence of renal cell carcinoma cells, wherein the kit comprises antibodies specific for selected markers, wherein the markers comprise or are selected from
25 the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

Additionally the invention provides a kit for assessing the renal cell carcinoma carcinogenic potential of a test compound. The kit comprises renal cell carcinoma cells and reagents for assessing kallikrein markers, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

30 In an aspect the invention provides a method of treating a patient afflicted with renal cell carcinoma comprising providing to cells of a patient antisense oligonucleotides complementary to polynucleotides encoding one or more kallikrein polypeptides, which are overexpressed in renal cell carcinoma. In an alternative method, expression of genes corresponding to one or more kallikrein polypeptides which are underexpressed in renal cell carcinoma are increased.

35 The invention relates to a method of inhibiting renal cell carcinoma in a patient at risk for developing renal cell carcinoma comprising inhibiting or increasing expression (or overexpression) of genes encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, that are either overexpressed or underexpressed, in renal cell carcinoma.

- 7 -

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to newly discovered correlations between expression of certain markers and renal cell carcinoma. The combinations of markers described herein may provide sensitive methods for detecting renal cell carcinoma. The levels of expression of a combination of markers described herein may correlate with the presence of renal cell carcinoma or a pre-malignant condition in a patient. Methods are provided for detecting the presence of renal cell carcinoma in a sample, the absence of renal cell carcinoma in a sample, the stage of a renal cell carcinoma, the grade of a renal cell carcinoma, the benign or malignant nature of a renal cell carcinoma, the metastatic potential of a renal cell carcinoma, assessing the histological type of neoplasm associated with the renal cell carcinoma, the indolence or aggressiveness of the cancer, and other characteristics of renal cell carcinoma that are relevant to prevention, diagnosis, characterization, and therapy of renal cell carcinoma in a patient. Methods are also provided for assessing the efficacy of one or more test agents for inhibiting renal cell carcinoma, assessing the efficacy of a therapy for renal cell carcinoma, monitoring the progression of renal cell carcinoma, selecting an agent or therapy for inhibiting renal cell carcinoma, treating a patient afflicted with renal cell carcinoma, inhibiting renal cell carcinoma in a patient, and assessing the carcinogenic potential of a test compound.

Glossary

The terms "sample", "biological sample", and the like, mean a material known or suspected of expressing or containing kallikrein polypeptides associated with renal cell carcinoma, or polynucleotides encoding the polypeptides. The test sample can be used directly as obtained from the source or following a pretreatment to modify the character of the sample. The sample can be derived from any biological source, such as tissues, extracts, or cell cultures, including cells (e.g. tumor cells), cell lysates, and physiological fluids, such as, for example, whole blood, plasma, serum, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, synovial fluid, peritoneal fluid and the like. The sample can be obtained from animals, preferably mammals, most preferably humans. The sample can be treated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of interfering components, the addition of reagents, and the like. Nucleic acids and polypeptides may be isolated from the samples and utilized in the methods of the invention. In a preferred embodiment, the sample is a serum sample.

The term "subject" or "patient" refers to a warm-blooded animal such as a mammal, which is suspected of having renal cell carcinoma or a condition, disease, or syndrome associated with renal cell carcinoma. Preferably, "subject" refers to a human.

"Kallikrein polypeptides" or "kallikrein markers" include one or more of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The term includes the native-sequence polypeptides, isoforms, precursors and chimeric polypeptides. The amino acid sequences for native kallikrein polypeptides employed in the

- 8 -

present invention include the sequences found in GenBank for each polypeptide as shown in Table 1, and in SEQ ID NO: 1 (kallikrein 5), NO. 4 (kallikrein 6), NO. 8 (kallikrein 10), and NOs. 11 and 12 (kallikrein 11), or a portion thereof. Other useful polypeptides are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity), and preferably retain the immunogenic activity of the corresponding native-sequence kallikrein polypeptide.

A "native-sequence polypeptide" comprises a polypeptide having the same amino acid sequence of a polypeptide derived from nature. Such native-sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.

The term "native-sequence polypeptide" specifically encompasses naturally occurring truncated or secreted forms of a polypeptide, polypeptide variants including naturally occurring variant forms (e.g., alternatively spliced forms or splice variants), and naturally occurring allelic variants.

The term "polypeptide variant" means a polypeptide having at least about 70-80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with a native-sequence polypeptide, in particular having at least 70-80%, 85%, 90%, 95% amino acid sequence identity to the sequences identified in the GenBank Accession Nos. in Table 1 and shown in SEQ ID NOS 1, 4, 8, 11, and 12. Such variants include, for instance, polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of SEQ ID NOS: 1, 4, 8, 11, and 12, including variants from other species, but excludes a native-sequence polypeptide.

An allelic variant may also be created by introducing substitutions, additions, or deletions into a nucleic acid encoding a native polypeptide sequence such that one or more amino acid substitutions, additions, or deletions are introduced into the encoded protein. Mutations may be introduced by standard methods, such as site-directed mutagenesis and PCR-mediated mutagenesis. In an embodiment, conservative substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue with a similar side chain. Amino acids with similar side chains are known in the art and include amino acids with basic side chains (e.g. Lys, Arg, His), acidic side chains (e.g. Asp, Glu), uncharged polar side chains (e.g. Gly, Asp, Glu, Ser, Thr, Tyr and Cys), nonpolar side chains (e.g. Ala, Val, Leu, Iso, Pro, Trp), beta-branched side chains (e.g. Thr, Val, Iso), and aromatic side chains (e.g. Tyr, Phe, Trp, His). Mutations can also be introduced randomly along part or all of the native sequence, for example, by saturation mutagenesis. Following mutagenesis the variant polypeptide can be recombinantly expressed and the activity of the polypeptide may be determined.

Polypeptide variants include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of a native polypeptide which include fewer amino acids than the full length polypeptides. A portion of a polypeptide can be a polypeptide which is for example, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids in length. Portions in which regions of a polypeptide are deleted can be prepared by recombinant techniques and can be evaluated for one or more functional activities such as the ability to form antibodies specific for a polypeptide.

- 9 -

A naturally occurring allelic variant may contain conservative amino acid substitutions from the native polypeptide sequence or it may contain a substitution of an amino acid from a corresponding position in a kallikrein polypeptide homolog, for example, the murine kallikrein polypeptide.

Percent identity of two amino acid sequences, or of two nucleic acid sequences identified herein is defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical with the amino acid residues in a kallikrein polypeptide or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid or nucleic acid sequence identity can be achieved in various conventional ways, for instance, using publicly available computer software including the GCG program package (Devereux J. et al., *Nucleic Acids Research* 12(1): 387, 1984); BLASTP, BLASTN, and FASTA (Atschul, S.F. et al. *J. Molec. Biol.* 215: 403-410, 1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCBI NLM NIH Bethesda, Md. 20894; Altschul, S. et al. *J. Mol. Biol.* 215: 403-410, 1990). Skilled artisans can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Methods to determine identity and similarity are codified in publicly available computer programs.

Kallikrein polypeptides include chimeric or fusion proteins. A "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of a kallikrein polypeptide operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same kallikrein polypeptide). Within the fusion protein, the term "operably linked" is intended to indicate that the kallikrein polypeptide and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of the kallikrein polypeptide. A useful fusion protein is a GST fusion protein in which a kallikrein polypeptide is fused to the C-terminus of GST sequences. Another example of a fusion protein is an immunoglobulin fusion protein in which all or part of a kallikrein polypeptide is fused to sequences derived from a member of the immunoglobulin protein family. Chimeric and fusion proteins can be produced by standard recombinant DNA techniques.

Kallikrein polypeptides may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

"Kallikrein polynucleotides" or "polynucleotides encoding kallikrein polypeptides" refers to one or more of kallikrein 5 polynucleotide (KLK5), kallikrein 6 polynucleotide (KLK6), kallikrein 10 polynucleotide (KLK10), and kallikrein 11 polynucleotide (KLK11). The term includes polynucleotides that encode a native-sequence polypeptide, a polypeptide variant including a portion of a kallikrein polypeptide, an isoform, precursor, and chimeric polypeptide.

The polynucleotide sequences encoding native kallikrein polypeptides employed in the present invention include the nucleic acid sequences of the GenBank Accession Nos. identified in Table 1, and in SEQ ID NOS: 2 and 3 (KLK5), NOS. 5, 6, and 7 (KLK6), NOS. 9 and 10 (KLK10), and NOS. 13 and 14 (KLK11), or a fragment thereof.

Polynucleotides encoding kallikrein polypeptides include nucleic acid sequences complementary to these nucleic acids, and polynucleotides that are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity).

5 Kallikrein polynucleotides also include sequences which differ from a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 3, 5, 6, 7, 9, 10, 13, and 14, due to degeneracy in the genetic code. As one example, DNA sequence polymorphisms within the nucleotide sequence of a kallikrein polypeptide may result in silent mutations that do not affect the amino acid sequence. Variations in one or more nucleotides may exist among individuals within a population due to
10 natural allelic variation. DNA sequence polymorphisms may also occur which lead to changes in the amino acid sequence of a kallikrein polypeptide.

Kallikrein polynucleotides also include nucleic acids that hybridize under stringent conditions, preferably high stringency conditions to a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 3, 5, 6, 7, 9, 10, 13, and 14. Appropriate stringency conditions which
15 promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C may be employed. The stringency may be selected based on the conditions used in the wash step. By way of example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In
20 addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

Kallikrein polynucleotides also include truncated nucleic acids or nucleic acid fragments and variant forms of the nucleic acids that arise by alternative splicing of an mRNA corresponding to a DNA.

Kallikrein polynucleotides are intended to include DNA and RNA (e.g. mRNA) and can be either double stranded or single stranded. A polynucleotide may, but need not, include additional coding or non-
25 coding sequences, or it may, but need not, be linked to other molecules and/or carrier or support materials. The polynucleotides for use in the methods of the invention may be of any length suitable for a particular method.

One or more kallikrein polypeptides or kallikrein polynucleotides are detected in the present invention. In an aspect, the kallikrein polypeptides comprise kallikrein 6; kallikrein 6 and kallikrein 10;
30 kallikrein 6 and kallikrein 11; kallikrein 6, kallikrein 10 and kallikrein 11; or kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11. In another aspect, the kallikrein polynucleotides comprise KLK6; KLK6 and KLK10; KLK6 and KLK11; KLK6, KLK10 and KLK11; or KLK5, KLK6, KLK10 and KLK11

General Methods

A variety of methods can be employed for the diagnostic and prognostic evaluation of renal cell
35 carcinoma involving kallikrein polypeptides, and polynucleotides encoding the polypeptides, and the identification of subjects with a predisposition to such disorders. Such methods may, for example, utilize polynucleotides encoding kallikrein polypeptides, and fragments thereof, and binding agents (e.g. antibodies aptamers) against kallikrein polypeptides, including peptide fragments. In particular, the polynucleotides and antibodies may be used, for example, for (1) the detection of either over- or under-expression of kallikrein

polynucleotides, relative to a non-disorder state; and (2) the detection of either an over- or an under-abundance of kallikrein polypeptides, relative to a non-disorder state or the presence of modified (e.g., less than full length) kallikrein polypeptides that correlate with a disorder state, or a progression toward a disorder state.

5 The invention also contemplates a method for detecting renal cell carcinoma comprising producing a profile of levels of kallikrein polypeptides in cells from a patient, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 10, and/or kallikrein 11, and comparing the profile with a reference to identify a protein profile for the test cells indicative of disease.

10 The methods described herein may be used to evaluate the probability of the presence of malignant or pre-malignant cells, for example, in a group of cells freshly removed from a host. Such methods can be used to detect tumors, quantitate their growth, and help in the diagnosis and prognosis of disease. The methods can be used to detect the presence of cancer metastasis, as well as confirm the absence or removal of all tumor tissue following surgery, cancer chemotherapy, and/or radiation therapy. They can further be used to monitor cancer chemotherapy and tumor reappearance.

15 The methods described herein can be adapted for diagnosing and monitoring renal cell carcinoma by detecting kallikrein polypeptides, or polynucleotides encoding the polypeptides in biological samples from a subject. These applications require that the amount of polypeptides or polynucleotides quantitated in a sample from a subject being tested be compared to a predetermined standard. The standard may correspond to levels quantitated for another sample or an earlier sample from the subject, or levels quantitated for a control sample. Levels for control samples from healthy subjects or renal cell carcinoma subjects may be established by prospective and/or retrospective statistical studies. Healthy or normal subjects who have no clinically evident disease or abnormalities may be selected for statistical studies. Diagnosis may be made by a finding of statistically different levels of kallikrein polypeptides, or polynucleotides encoding same, compared to a control sample or previous levels quantitated for the same subject. A "significant difference" 25 in levels of markers or polynucleotides in a patient sample compared to a control or standard (e.g. normal levels or levels in other samples from a patient) may represent levels that are higher or lower than the standard error of the detection assay, preferably the levels are at least about 1.5, 2, 3, 4, 5, or 6 times higher or lower, respectively, than the control or standard. The difference in levels of markers or polynucleotides may be a statistically significant difference.

30 In an embodiment, the levels of kallikrein markers, in particular kallikrein 6 and kallikrein 10, are significantly higher in subjects with renal cell carcinoma, more particularly renal cell carcinoma with tumors of high grade and/or advanced stage. In another embodiment, there is a statistically significant difference in kallikrein 6 levels and/or kallikrein 10 levels which are indicative of late stage disease and/or reduced disease survival.

35 **Nucleic Acid Methods/Assays**

As noted herein renal cell carcinoma may be detected based on the level of polynucleotides encoding kallikrein polypeptides in a sample. Techniques for detecting nucleic acid molecules such as polymerase chain reaction (PCR) and hybridization assays are well known in the art.

Nucleotide probes for use in the detection of nucleic acid sequences in samples may be constructed using conventional methods known in the art. Suitable probes may be based on nucleic acid sequences encoding at least 5 sequential amino acids from regions of polynucleotides encoding kallikrein polypeptides, preferably they comprise 15 to 40 nucleotides. A nucleotide probe may be labeled with a detectable substance such as a radioactive label that provides for an adequate signal and has sufficient half-life such as ^{32}P , ^3H , ^{14}C or the like. Other detectable substances that may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labeled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect polynucleotides encoding kallikrein polypeptides preferably in human cells. The nucleotide probes may also be useful in the diagnosis of renal cell carcinoma involving polynucleotides encoding kallikrein polypeptides, in monitoring the progression of such disorder; or monitoring a therapeutic treatment.

Probes may be used in hybridization techniques to detect polynucleotides encoding kallikrein polypeptides. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from a patient or other cellular source with probes under conditions favorable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of nucleic acids that have hybridized to the probe if any are detected.

The detection of polynucleotides encoding kallikrein polypeptides, may involve the amplification of specific gene sequences using an amplification method such as polymerase chain reaction (PCR), followed by the analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed by one of skill in the art.

By way of example, oligonucleotide primers may be employed in a PCR based assay to amplify a portion of polynucleotides encoding kallikrein polypeptides, derived from a sample, wherein the oligonucleotide primers are specific for (i.e. hybridize to) polynucleotides encoding each of the kallikrein polypeptides. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis.

In order to maximize hybridization under assay conditions, primers and probes employed in the methods of the invention generally have at least about 60%, preferably at least about 75% and more preferably at least about 90% identity to a portion of polynucleotides encoding kallikrein polypeptides. The primers and probes may be at least 10 nucleotides, and preferably at least 20 nucleotides in length. In an embodiment the primers and probes are at least about 10-40 nucleotides in length.

Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of expression of polynucleotides encoding kallikrein polypeptides. For example, RNA may be isolated from a cell type or tissue known to express these polynucleotides and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein.

The primers and probes may be used in the above-described methods *in situ* i.e directly on tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections.

In an aspect of the invention, a method is provided employing reverse transcriptase-polymerase chain reaction (RT-PCR), in which PCR is applied in combination with reverse transcription. Generally, RNA is extracted from a sample tissue using standard techniques (for example, guanidine isothiocyanate extraction as described by Chomcynski and Sacchi, Anal. Biochem. 162:156-159, 1987) and is reverse transcribed to produce cDNA. The cDNA is used as a template for a polymerase chain reaction. The cDNA is hybridized to sets of primers specifically designed against a kallikrein polynucleotide sequence. Once the primer and template have annealed a DNA polymerase is employed to extend from the primer, to synthesize a copy of the template. The DNA strands are denatured, and the procedure is repeated many times until sufficient DNA is generated to allow visualization by ethidium bromide staining and agarose gel electrophoresis.

Amplification may be performed on samples obtained from a subject with suspected renal cell carcinoma and an individual who is not afflicted with renal cell carcinoma. The reaction may be performed on several dilutions of cDNA spanning at least two orders of magnitude. A statistically significant difference in expression in several dilutions of the subject sample as compared to the same dilutions of the non-cancerous sample may be considered positive for the presence of renal cell carcinoma.

Oligonucleotides or longer fragments derived from polynucleotides encoding each kallikrein polypeptide may be used as targets in a microarray. The microarray can be used to simultaneously monitor the expression levels of large numbers of genes. The information from the microarray may be used to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

The preparation, use, and analysis of microarrays are well known to a person skilled in the art. (See, for example, Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995), PCT Application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)

Thus the invention also includes an array comprising polynucleotides encoding kallikrein marker(s). The array can be used to assay expression of kallikrein polynucleotides in the array. The invention allows the quantitation of expression of polynucleotides encoding kallikrein markers.

In an embodiment, the array can be used to monitor the time course of expression of kallikrein polynucleotides in the array. This can occur in various biological contexts such as tumor progression.

The array is also useful for ascertaining differential expression patterns of kallikrein polynucleotides in normal and abnormal cells. This provides a battery of polynucleotides that could serve as molecular targets for diagnosis or therapeutic intervention.

35 **Protein Methods**

Binding agents specific for kallikrein polypeptides may be used for a variety of diagnostic and assay applications. There are a variety of assay formats known to the skilled artisan for using a binding agent to detect a target molecule in a sample. (For example, see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988). In general, the presence or absence of an renal cell

carcinoma in a subject may be determined by (a) contacting a sample from the subject with binding agents for kallikrein polypeptides; (b) detecting in the sample levels of polypeptides that bind to the binding agents; and (c) comparing the levels of polypeptides with a predetermined standard or cut-off value.

“Binding agent” refers to a substance such as a polypeptide or antibody that specifically binds to a kallikrein polypeptide. A substance “specifically binds” to a polypeptide if it reacts at a detectable level with the kallikrein polypeptide, and does not react detectably with peptides containing unrelated sequences or sequences of different polypeptides. Binding properties may be assessed using an ELISA, which may be readily performed by those skilled in the art (see for example, Newton et al, Develop. Dynamics 197: 1-13, 1993).

A binding agent may be a ribosome, with or without a peptide component, an aptamer, an RNA molecule, or a polypeptide. A binding agent may be a polypeptide that comprises a kallikrein polypeptide sequence, a peptide variant thereof, or a non-peptide mimetic of such a sequence. By way of example a kallikrein polypeptide sequence may be a peptide portion of a kallikrein polypeptide that is capable of modulating a function mediated by the kallikrein polypeptide.

An aptamer includes a DNA or RNA molecule that binds to polynucleotides and polypeptides. An aptamer that binds to a polypeptide (or binding domain) of a kallikrein polypeptide or a polynucleotide encoding a kallikrein polypeptide can be produced using conventional techniques, without undue experimentation. [For example, see the following publications describing *in vitro* selection of aptamers: Klug et al., Mol. Biol. Reports 20:97-107 (1994); Wallis et al., Chem. Biol. 2:543-552 (1995); Ellington, Curr. Biol. 4:427-429 (1994); Lato et al., Chem. Biol. 2:291-303 (1995); Conrad et al., Mol. Div. 1:69-78 (1995); and Uphoff et al., Curr. Opin. Struct. Biol. 6:281-287 (1996)].

In certain other preferred embodiments, the binding agent is an antibody.

In an aspect the present invention provides a diagnostic method for monitoring or diagnosing renal cell carcinoma in a subject by quantitating kallikrein polypeptides, in a biological sample from the subject comprising reacting the sample with antibodies specific for kallikrein polypeptides, which are directly or indirectly labelled with detectable substances, and detecting the detectable substances.

In an aspect of the invention, a method for detecting renal cell carcinoma is provided comprising:

- (a) obtaining a sample suspected of containing kallikrein polypeptides associated with renal cell carcinoma, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11;
- (b) contacting the sample with antibodies that specifically bind kallikrein polypeptides, under conditions effective to bind the antibodies and form complexes;
- (c) measuring the amount of kallikrein polypeptides, present in the sample by quantitating the amount of the complexes; and
- (d) comparing the amount of kallikrein polypeptides, present in the samples with the amount of polypeptides in a control, wherein a change or significant difference in the amount of polypeptides in the sample compared with the amount in the control is indicative of renal cell carcinoma.

- 15 -

In an embodiment, the invention contemplates a method for monitoring the progression of renal cell carcinoma in an individual, comprising:

- 5 (a) contacting antibodies which bind to kallikrein polypeptides, with a sample from the individual so as to form binary complexes comprising each of the antibodies and polypeptides in the sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11;
- (b) determining or detecting the presence or amount of complex formation in the sample;
- (c) repeating steps (a) and (b) at a point later in time; and
- 10 (d) comparing the result of step (b) with the result of step (c), wherein a difference in the amount of complex formation is indicative of the stage and/or progression of the renal cell carcinoma in said individual.

The amount of complexes may also be compared to a value representative of the amount of the complexes from an individual not at risk of, or afflicted with, renal cell carcinoma at different stages.

Thus, antibodies specifically reactive with a kallikrein polypeptide, or derivatives, such as enzyme
15 conjugates or labeled derivatives, may be used to detect a kallikrein polypeptide, in various samples (e.g. biological materials). They may be used as diagnostic or prognostic reagents and they may be used to detect abnormalities in the levels of expression of kallikrein polypeptides, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular location of kallikrein polypeptides. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on renal cell carcinoma involving
20 kallikrein polypeptides, and other conditions. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies.

Antibodies may be used in any known immunoassays that rely on the binding interaction between antigenic determinants of kallikrein polypeptides, and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex
25 agglutination, hemagglutination, and histochemical tests. These terms are well understood by those skilled in the art. A person skilled in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

In particular, the antibodies may be used in immunohistochemical analyses, for example, at the cellular and sub-subcellular level, to detect kallikrein polypeptides, to localize them to particular renal cell
30 carcinoma tumor cells and tissues, and to specific subcellular locations, and to quantitate the level of expression.

Antibodies for use in the present invention include monoclonal or polyclonal antibodies, immunologically active fragments (e.g. a Fab or (Fab)₂ fragments), antibody heavy chains, humanized antibodies, antibody light chains, genetically engineered single chain F_v molecules (Ladner et al, U.S. Pat.
35 No. 4,946,778), chimeric antibodies, for example, antibodies which contain the binding specificity of murine antibodies, but in which the remaining portions are of human origin, or derivatives, such as enzyme conjugates or labeled derivatives.

Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art. Isolated native or recombinant kallikrein

- 16 -

polypeptides may be utilized to prepare antibodies. See, for example, Kohler et al. (1975) *Nature* 256:495-497; Kozbor et al. (1985) *J. Immunol Methods* 81:31-42; Cote et al. (1983) *Proc Natl Acad Sci* 80:2026-2030; and Cole et al. (1984) *Mol Cell Biol* 62:109-120 for the preparation of monoclonal antibodies; Huse et al. (1989) *Science* 246:1275-1281 for the preparation of monoclonal Fab fragments; and, Pound (1998) *Immunochemical Protocols*, Humana Press, Totowa, N.J for the preparation of phagemid or B-lymphocyte immunoglobulin libraries to identify antibodies. The antibodies specific for kallikrein polypeptides used in the methods of the invention may also be obtained from scientific or commercial sources.

In an embodiment of the invention, antibodies are reactive against kallikrein polypeptides if they bind with a K_a of greater than or equal to 10^{-7} M.

Antibodies that bind to kallikrein polypeptides may be labelled with a detectable substance and localised in biological samples based upon the presence of the detectable substance. Examples of detectable substances include, but are not limited to, the following: radioisotopes (e.g., ^3H , ^{14}C , ^{35}S , ^{125}I , ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent labels such as luminol, enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase), biotinyl groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods), and predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against a kallikrein polypeptide. The second antibody may be labeled with a detectable substance to detect the primary antigen-antibody reaction. By way of example, if the antibody having specificity against a kallikrein polypeptide is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

Methods for conjugating or labelling the antibodies discussed above may be readily accomplished by one of ordinary skill in the art. (See for example Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques*, Enzyme Purification: Part B, Jakoby and Wichek (eds.), Academic Press, New York, p. 30, 1974; and Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988 re methods for conjugating or labelling the antibodies with enzyme or ligand binding partner).

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect kallikrein polypeptides. Generally, antibodies may be labeled with detectable substances and kallikrein polypeptides, may be localised in tissues and cells based upon the presence of the detectable substance.

In the context of the methods of the invention, the sample, binding agents (e.g. antibodies) for kallikrein polypeptides may be immobilized on a carrier or support. Examples of suitable carriers or

supports are agarose, cellulose, nitrocellulose, dextran, Sephadex, Sepharose, liposomes, carboxymethyl cellulose, polyacrylamides, polystyrene, gabbros, filter paper, magnetite, ion-exchange resin, plastic film, plastic tube, glass, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The support material may have any possible configuration including spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test strip). Thus, the carrier may be in the shape of, for example, a tube, test plate, well, beads, disc, sphere, etc. The immobilized material may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical methods, for example, cyanogen bromide coupling. Binding agents (e.g. antibodies) may be indirectly immobilized using second binding agents specific for the first binding agent. For example, mouse antibodies specific for a kallikrein polypeptide may be immobilized using sheep anti-mouse IgG Fc fragment specific antibody coated on the carrier or support.

Where radioactive labels are used as a detectable substance, kallikrein polypeptides may be localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

Time-resolved fluorometry may be used to detect a signal. For example, the method described in Christopoulos TK and Diamandis EP Anal Chem 1992:64:342-346 may be used with a conventional time-resolved fluorometer.

Therefore, in accordance with an embodiment of the invention, a method is provided wherein antibodies specific for each kallikrein polypeptide, are labelled with enzymes, substrates for the enzymes are added wherein the substrates are selected so that the substrates, or a reaction product of the enzymes and substrates, form fluorescent complexes with lanthanide metals. Lanthanide metals are added and the kallikrein polypeptides are quantitated in the sample by measuring fluorescence of the fluorescent complexes. Antibodies specific for the kallikrein polypeptides may be directly or indirectly labelled with enzymes. Enzymes are selected based on the ability of a substrate of the enzyme, or a reaction product of the enzyme and substrate, to complex with lanthanide metals such as europium and terbium. Examples of suitable enzymes include alkaline phosphatase and β -galactosidase.

Examples of enzymes and substrates for enzymes that provide such fluorescent complexes are described in U.S. Patent No. 5,312,922 to Diamandis. By way of example, when the antibody is directly or indirectly labelled with alkaline phosphatase the substrate employed in the method may be 4-methylumbelliferyl phosphate, 5-fluorosalicyl phosphate, or diflunisal phosphate. The fluorescence intensity of the complexes is typically measured using a time-resolved fluorometer e.g. a CyberFluor 615 Imunoanalyzer (Nordion International, Kanata, Ontario).

Antibodies specific for kallikrein polypeptides may also be indirectly labelled with enzymes. For example, an antibody may be conjugated to one partner of a ligand binding pair, and the enzyme may be coupled to the other partner of the ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein. In another embodiment, antibodies specific for the anti-kallikrein antibodies are labeled with an enzyme.

In accordance with an embodiment, the present invention provides means for determining kallikrein polypeptides in a sample, in particular a serum sample, by measuring kallikrein polypeptides by

- 18 -

immunoassay. It will be evident to a skilled artisan that a variety of immunoassay methods can be used to measure kallikrein polypeptides in serum. In general, an immunoassay method may be competitive or noncompetitive. Competitive methods typically employ immobilized or immobilizable antibodies to the kallikrein polypeptides and a labeled form of each of the kallikrein polypeptides. Kallikrein polypeptides and labeled kallikrein polypeptides compete for binding to anti-kallikrein antibodies. After separation of the resulting labeled kallikrein polypeptides that have become bound to anti-kallikrein polypeptides (bound fraction) from that which has remained unbound (unbound fraction), the amount of the label in either bound or unbound fraction is measured and may be correlated with the amount of kallikrein polypeptides, in the test sample in any conventional manner, e.g., by comparison to a standard curve.

10 In an aspect, a non-competitive method is used for the determination of kallikrein polypeptides with the most common method being the "sandwich" method. In this assay, two types of antibodies specific for kallikrein polypeptides are employed. One type of antibody is directly or indirectly labeled (sometimes referred to as the "detection antibody") and the other is immobilized or immobilizable (sometimes referred to as the "capture antibody"). The capture and detection antibodies can be contacted simultaneously or sequentially with a test sample. Sequential methods can be accomplished by incubating capture antibodies with the sample, and adding the detection antibodies at a predetermined time thereafter (sometimes referred to as the "forward" method); or the detection antibodies can be incubated with the sample first and then the capture antibodies added (sometimes referred to as the "reverse" method). After the necessary incubation(s) have occurred, to complete the assay, the capture antibodies are separated from the liquid test mixture, and labels are measured in at least a portion of the separated capture antibody phase or the remainder of the liquid test mixture. Generally the labels are measured in the capture antibody phase since it comprises kallikrein polypeptides bound by ("sandwiched" between) the capture and detection antibodies. In an embodiment, the label may be measured without separating the capture antibodies and liquid test mixture.

25 In a typical two-site immunometric assay for kallikrein polypeptides, one or both of the capture and detection antibodies are polyclonal antibodies or one or both of the capture and detection antibodies are monoclonal antibodies (i.e. polyclonal/polyclonal, monoclonal/monoclonal, or monoclonal/polyclonal). The labels used with the detection antibodies can be selected from any of those known conventionally in the art. The labels may be an enzyme or a chemiluminescent moiety, but it can also be a radioactive isotope, a fluorophor, a detectable ligand (e.g., detectable by a secondary binding by a labeled binding partner for the ligand), and the like. Preferably antibodies are labelled with enzymes which are detected by adding substrates that are selected so that a reaction product of the enzymes and substrates forms fluorescent complexes. Capture antibodies may be selected so that they provide a means for being separated from the remainder of the test mixture. Accordingly, the capture antibodies can be introduced to the assay in an already immobilized or insoluble form, or can be in an immobilizable form, that is, a form which enables immobilization to be accomplished subsequent to introduction of the capture antibodies to the assay. An immobilized capture antibody may comprise an antibody covalently or noncovalently attached to a solid phase such as a magnetic particle, a latex particle, a microtiter plate well, a bead, a cuvette, or other reaction vessel. An example of an immobilizable capture antibody is antibody which has been chemically modified with a ligand moiety, e.g., a hapten, biotin, or the like, and which can be subsequently immobilized by

contact with an immobilized form of a binding partner for the ligand, e.g., an antibody, avidin, or the like. In an embodiment, a capture antibody may be immobilized using a species specific antibody for the capture antibody that is bound to the solid phase.

5 A particular sandwich immunoassay method of the invention employs two types of antibodies, first antibodies are reactive against kallikrein polypeptides and second antibodies having specificity against antibodies reactive against kallikrein polypeptides labelled with enzymatic labels, and fluorogenic substrates for the enzymes. An enzyme may be alkaline phosphatase (ALP) and the substrate is 5-fluorosalicyl phosphate. ALP cleaves phosphate out of the fluorogenic substrate, 5-fluorosalicyl phosphate, to produce 5-fluorosalicylic acid (FSA). 5-Fluorosalicylic acid can then form a highly fluorescent ternary complex of the
10 form FSA-Tb(3+)-EDTA, which can be quantified by measuring the Tb3+ fluorescence in a time-resolved mode. Fluorescence intensity is measured using a time-resolved fluorometer as described herein.

The above-described immunoassay methods and formats are intended to be exemplary and are not limiting.

Computer Systems

15 Computer readable media comprising kallikrein markers is also provided. "Computer readable media" refers to any medium that can be read and accessed directly by a computer, including but not limited to magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. Thus, the invention contemplates computer readable
20 medium having recorded thereon markers identified for patients and controls.

"Recorded" refers to a process for storing information on computer readable medium. The skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising information on kallikrein markers.

A variety of data processor programs and formats can be used to store information on kallikrein
25 markers on computer readable medium. For example, the information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. Any number of dataprocessor structuring formats (e.g., text file or database) may be adapted in order to obtain computer readable medium having recorded thereon the marker information.

30 By providing the marker information in computer readable form, one can routinely access the information for a variety of purposes. For example, one skilled in the art can use the information in computer readable form to compare marker information obtained during or following therapy with the information stored within the data storage means.

The invention provides a medium for holding instructions for performing a method for determining
35 whether a patient has renal cell carcinoma or a pre-disposition to renal cell carcinoma, comprising determining the presence or absence of kallikrein markers or polynucleotides encoding same, and based on the presence or absence of the kallikrein markers or polynucleotides encoding same, determining whether the patient has renal cell carcinoma or a pre-disposition to renal cell carcinoma, and optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

- 20 -

The invention also provides in an electronic system and/or in a network, a method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same, comprising determining the presence or absence of kallikrein markers or polynucleotides encoding same, and based on the presence or absence of the kallikrein markers or polynucleotides encoding same, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma, and optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention further provides in a network, a method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same, comprising: (a) receiving phenotypic information on the subject and information on kallikrein markers or polynucleotides encoding same, associated with samples from the subject; (b) acquiring information from the network corresponding to the kallikrein markers or polynucleotides encoding same; and (c) based on the phenotypic information and information on the kallikrein markers or polynucleotides encoding same, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma; and (d) optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention still further provides a system for identifying selected records that identify a renal cell carcinoma cell. A system of the invention generally comprises a digital computer; a database server coupled to the computer; a database coupled to the database server having data stored therein, the data comprising records of data comprising kallikrein markers, or polynucleotides encoding same, and a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records which match the desired selection criteria.

In an aspect of the invention a method is provided for detecting a renal cell carcinoma cell using a computer having a processor, memory, display, and input/output devices, the method comprising the steps of:

- (a) creating records of kallikrein markers or polynucleotides encoding same, isolated from a sample suspected of containing an renal cell carcinoma cell;
- (b) providing a database comprising records of data comprising kallikrein markers, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and/or comprising polynucleotides encoding same; and
- (c) using a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records of step (a) which provide a match of the desired selection criteria of the database of step (b) the presence of a match being a positive indication that the markers of step (a) have been isolated from a cell that is a renal cell carcinoma cell.

The invention contemplates a business method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same comprising: (a) receiving phenotypic information on the subject and information on kallikrein markers or polynucleotides encoding same, associated with samples from the subject; (b) acquiring

- information from a network corresponding to the kallikrein markers or polynucleotides encoding same; and (c) based on the phenotypic information, information on the kallikrein markers or polynucleotides encoding same, and acquired information, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma; and (d) optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

Imaging Methods

Antibodies specific for kallikrein polypeptides may also be used in imaging methodologies in the management of renal cell carcinoma. The invention provides a method for imaging tumors associated with kallikrein polypeptides.

- In an embodiment the method is an *in vivo* method and a subject or patient is administered imaging agents that carry imaging labels and are capable of targeting or binding to kallikrein polypeptides. In the method each imaging agent is labeled so that it can be distinguished during the imaging. The imaging agents are allowed to incubate *in vivo* and bind to the kallikrein polypeptides associated with renal cell carcinoma tumors. The presence of label is localized to the renal cell carcinoma, and the localized label is detected using imaging devices known to those skilled in the art.

- The imaging agents may be antibodies or chemical entities that recognize kallikrein polypeptides. In an aspect of the invention an imaging agent is a polyclonal antibody or monoclonal antibody, or fragments thereof, or constructs thereof including but not limited to, single chain antibodies, bifunctional antibodies, molecular recognition units, and peptides or entities that mimic peptides. The antibodies specific for kallikrein polypeptides used in the methods of the invention may be obtained from scientific or commercial sources, or isolated native or recombinant kallikrein polypeptides may be utilized to prepare antibodies etc as described herein.

- An imaging agent may be a peptide that mimics the epitope for an antibody specific for a kallikrein polypeptide and binds to a kallikrein polypeptide. The peptide may be produced on a commercial synthesizer using conventional solid phase chemistry. By way of example, a peptide may be prepared that includes tyrosine, lysine, or phenylalanine to which N_2S_2 chelate is complexed (See U.S. Patent No. 4,897,255). The anti-kallikrein peptide conjugate is then combined with a radiolabel (e.g. sodium ^{99m}Tc pertechnetate or sodium ^{188}Re perrhenate) and it may be used to locate a tumor producing the kallikrein polypeptides.

- Imaging agents carry labels to image the kallikrein polypeptides. Agents may be labelled for use in radionuclide imaging. In particular, agents may be directly or indirectly labelled with a radioisotope. Examples of radioisotopes that may be used in the present invention are the following: ^{277}Ac , ^{211}At , ^{128}Ba , ^{131}Ba , 7Be , ^{204}Bi , ^{205}Bi , ^{206}Bi , ^{76}Br , ^{77}Br , ^{82}Br , ^{109}Cd , ^{47}Ca , ^{11}C , ^{14}C , ^{36}Cl , ^{48}Cr , ^{51}Cr , ^{62}Cu , ^{64}Cu , ^{67}Cu , ^{165}Dy , ^{155}Eu , ^{18}F , ^{153}Gd , ^{66}Ga , ^{67}Ga , ^{68}Ga , ^{72}Ga , ^{198}Au , 3H , ^{166}Ho , ^{111}In , ^{113m}In , ^{115m}In , ^{123}I , ^{125}I , ^{131}I , ^{189}Ir , ^{191m}Ir , ^{192}Ir , ^{194}Ir , ^{52}Fe , ^{55}Fe , ^{59}Fe , ^{177}Lu , ^{15}O , $^{191m-191}Os$, ^{109}Pd , ^{32}P , ^{33}P , ^{42}K , ^{226}Ra , ^{186}Re , ^{188}Re , ^{82m}Rb , ^{153}Sm , ^{46}Sc , ^{47}Sc , ^{72}Se , ^{75}Se , ^{105}Ag , ^{22}Na , ^{24}Na , ^{89}Sr , ^{35}S , ^{38}S , ^{177}Ta , ^{96}Tc , ^{99m}Tc , ^{201}Tl , ^{202}Tl , ^{113}Sn , ^{117m}Sn , ^{121}Sn , ^{166}Yb , ^{169}Yb , ^{175}Yb , ^{88}Y , ^{90}Y , ^{62}Zn and ^{65}Zn . Preferably the radioisotope is ^{131}I , ^{125}I , ^{123}I , ^{111}I , ^{99m}Tc , ^{90}Y , ^{186}Re , ^{188}Re , ^{32}P , ^{153}Sm , ^{67}Ga , ^{201}Tl , ^{77}Br , or ^{18}F , and it is imaged with a photoscanning device.

Procedures for labeling biological agents with the radioactive isotopes are generally known in the art. U.S. Pat. No. 4,302,438 describes tritium labeling procedures. Procedures for iodinating, tritium labeling,

and ^{35}S labeling especially adapted for murine monoclonal antibodies are described by Goding, J. W. (supra, pp 124-126) and the references cited therein. Other procedures for iodinating biological agents, such as antibodies, binding portions thereof, probes, or ligands, are described in the scientific literature (see Hunter and Greenwood, Nature 144:945 (1962), David et al., Biochemistry 13:1014-1021 (1974), and U.S. Pat. Nos. 3,867,517 and 4,376,110). Iodinating procedures for agents are described by Greenwood, F. et al., Biochem. J. 89:114-123 (1963); Marchalonis, J., Biochem. J. 113:299-305 (1969); and Morrison, M. et al., Immunochemistry, 289-297 (1971). $^{99\text{m}}\text{Tc}$ -labeling procedures are described by Rhodes, B. et al. in Burchiel, S. et al. (eds.), Tumor Imaging: The Radioimmunochemical Detection of Cancer, New York: Masson 111-123 (1982) and the references cited therein. Labelling of antibodies or fragments with technetium-99m are also described for example in U.S. Pat. No. 5,317,091, U.S. Pat. No. 4,478,815, U.S. Pat. No. 4,478,818, U.S. Pat. No. 4,472,371, U.S. Pat. No. Re 32,417, and U.S. Pat. No. 4,311,688. Procedures suitable for ^{111}In -labeling biological agents are described by Hnatowich, D. J. et al., J. Immunol. Methods, 65:147-157 (1983), Hnatowich, D. et al., J. Applied Radiation, 35:554-557 (1984), and Buckley, R. G. et al., F.E.B.S. 166:202-204 (1984).

An imaging agent may also be labeled with a paramagnetic isotope for purposes of an *in vivo* method of the invention. Examples of elements that are useful in magnetic resonance imaging include gadolinium, terbium, tin, iron, or isotopes thereof. (See, for example, Schaefer et al., (1989) JACC 14, 472-480; Shreve et al., (1986) Magn. Reson. Med. 3, 336-340; Wolf, G L., (1984) Physiol. Chem. Phys. Med. NMR 16, 93-95; Wesbey et al., (1984) Physiol. Chem. Phys. Med. NMR 16, 145-155; Runge et al., (1984) Invest. Radiol. 19, 408-415 for discussions on *in vivo* nuclear magnetic resonance imaging.)

In the case of radiolabeled agents, the agents may be administered to the patient, localized to the tumor having one or more kallikrein polypeptides with which the agents bind, and detected or "imaged" *in vivo* using known techniques such as radionuclear scanning using, for example, a gamma camera or emission tomography. [See for example, A. R. Bradwell et al., "Developments in Antibody Imaging", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin et al., (eds.), pp. 65-85 (Academic Press 1985)]. A positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can also be used where the radiolabel emits positrons (e.g., ^{11}C , ^{18}F , ^{15}O , and ^{13}N).

Whole body imaging techniques using radioisotope labeled agents can be used for locating both primary tumors and tumors which have metastasized. Antibodies specific for kallikrein polypeptides or fragments thereof having the same epitope specificity, are bound to a suitable radioisotope, or a combination thereof, and administered parenterally. For renal cell carcinoma, administration preferably is intravenous. The bio-distribution of the labels can be monitored by scintigraphy, and accumulations of the labels can be related to the presence of renal cell carcinoma cells. Whole body imaging techniques are described in U.S. Pat. Nos. 4,036,945 and 4,311,688. Other examples of agents useful for diagnosis and therapeutic use that can be coupled to antibodies and antibody fragments include metallothionein and fragments (see, U.S. Pat. No. 4,732,864). These agents are useful in diagnosis, staging and visualization of cancer, in particular renal cell carcinoma, so that surgical and/or radiation treatment protocols can be used more efficiently.

Screening Methods

The invention also contemplates methods for evaluating test agents or compounds for their ability to inhibit renal cell carcinoma or potentially contribute to renal cell carcinoma. Test agents and compounds include but are not limited to peptides such as soluble peptides including Ig-tailed fusion peptides, members of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids, phosphopeptides (including members of random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)2, and Fab expression library fragments, and epitope-binding fragments thereof)], nucleic acids (e.g. antisense, interference RNA) and small organic or inorganic molecules. The agents or compounds may be endogenous physiological compounds or natural or synthetic compounds.

The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, the method comprising comparing:

- (a) levels of kallikrein markers or polynucleotides encoding same in a first sample obtained from a patient and exposed to the test agent, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and
- (b) levels of the kallikrein markers or polynucleotides encoding same in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of kallikrein markers or polynucleotides encoding same in the first sample, relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting renal cell carcinoma in the patient.

The first and second samples may be portions of a single sample obtained from a patient or portions of pooled samples obtained from a patient.

In an aspect, the invention provides a method of selecting an agent for inhibiting renal cell carcinoma in a patient comprising:

- (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing kallikrein markers and/or polynucleotides encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
- (d) selecting one of the test agents which alters the levels of the kallikrein markers and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.

Still another aspect of the present invention provides a method of conducting a drug discovery business comprising:

- (a) providing one or more methods or assay systems for identifying agents that inhibit renal cell carcinoma in a patient;
- (b) conducting therapeutic profiling of agents identified in step (a), or further analogs thereof, for efficacy and toxicity in animals; and

- 24 -

- (c) formulating a pharmaceutical preparation including one or more agents identified in step (b) as having an acceptable therapeutic profile.

In certain embodiments, the subject method can also include a step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and may optionally include establishing a sales group for marketing the pharmaceutical preparation.

The invention also contemplates a method of assessing the renal cell carcinoma carcinogenic potential of a test compound comprising:

- (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and
- (b) comparing kallikrein markers and/or polynucleotides encoding same in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the markers in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses renal cell carcinoma carcinogenic potential.

Kits

The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising at least kallikrein polynucleotides or binding agents (e.g. antibodies) described herein, which may be conveniently used, e.g., in clinical settings, to screen and diagnose patients, and to screen and identify those individuals afflicted with or exhibiting a predisposition to renal cell carcinoma.

Thus, the invention also contemplates kits for carrying out the methods of the invention. Such kits typically comprise two or more components required for performing a diagnostic assay. Components include but are not limited to compounds, reagents, containers, and/or equipment.

In an embodiment, a container with a kit comprises binding agents as described herein. By way of example, the kit may contain antibodies specific for kallikrein polypeptides, antibodies against the antibodies labelled with enzymes, and substrates for the enzymes. The kit may also contain microtiter plate wells, standards, assay diluent, wash buffer, adhesive plate covers, and/or instructions for carrying out a method of the invention using the kit.

In an aspect of the invention, the kit includes antibodies or antibody fragments which bind specifically to epitopes of kallikrein polypeptides, and means for detecting binding of the antibodies to epitopes associated with tumor cells, either as concentrates (including lyophilized compositions), which may be further diluted prior to use or at the concentration of use, where the vials may include one or more dosages. Where the kits are intended for *in vivo* use, single dosages may be provided in sterilized containers, having the desired amount and concentration of agents. Containers that provide a formulation for direct use, usually do not require other reagents, as for example, where the kit contains radiolabelled antibody preparations for *in vivo* imaging.

A kit may be designed to detect the level of polynucleotides encoding kallikrein polypeptides in a sample. Such kits generally comprise oligonucleotide probes or primers, as described herein, that hybridize to polynucleotides encoding kallikrein polypeptides. Such oligonucleotides may be used, for example, within

- 25 -

a PCR or hybridization procedure. Additional components that may be present within the kits include second oligonucleotides and/or diagnostic reagents to facilitate detection of polynucleotides encoding kallikrein polypeptides.

5 The reagents suitable for applying the screening methods of the invention to evaluate compounds may be packaged into convenient kits described herein providing the necessary materials packaged into suitable containers.

Applications

10 Kallikrein polypeptides are targets for renal cell carcinoma immunotherapy. Such immunotherapeutic methods include the use of antibody therapy, *in vivo* vaccines, and *ex vivo* immunotherapy approaches.

In one aspect, the invention provides antibodies specific for kallikrein polypeptides that may be used systemically to treat renal cell carcinoma. Preferably antibodies are used that target the tumor cells but not the surrounding non-tumor cells and tissue. Thus, the invention provides a method of treating a patient susceptible to, or having a cancer that expresses kallikrein polypeptides comprising administering to the patient an effective amount of antibodies that bind specifically to kallikrein polypeptides. In another aspect, 15 the invention provides a method of inhibiting the growth of tumor cells expressing kallikrein polypeptides, comprising administering to a patient antibodies which bind specifically to kallikrein polypeptides in amounts effective to inhibit growth of the tumor cells. Antibodies specific for kallikrein polypeptides may also be used in a method for selectively inhibiting the growth of, or killing a cell expressing kallikrein polypeptides comprising reacting antibody immunoconjugates or immunotoxins with the cell in an amount 20 sufficient to inhibit the growth of, or kill the cell.

By way of example, unconjugated antibodies specific for kallikrein polypeptides may be introduced into a patient such that the antibodies bind to cancer cells expressing kallikrein polypeptides and mediate growth inhibition of such cells (including the destruction thereof), and the tumor, by mechanisms which may 25 include complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, altering the physiologic function of kallikrein polypeptides and/or the inhibition of ligand binding or signal transduction pathways. In addition to unconjugated antibodies, antibodies specific for kallikrein polypeptides, conjugated to therapeutic agents (e.g. immunoconjugates) may also be used therapeutically to deliver the agents directly to tumor cells expressing kallikrein polypeptides and thereby destroy the tumor. Examples of such agents include abrin, 30 ricin A, *Pseudomonas* exotoxin, or diphtheria toxin, proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, and biological response modifiers such as lymphokines, interleukin-1, interleukin-2, interleukin-6, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, or other growth factors.

Cancer immunotherapy using antibodies specific for kallikrein polypeptides may utilize the various 35 approaches that have been successfully employed for cancers, including but not limited to colon cancer (Arlén et al., 1998, Crit Rev Immunol 18: 133-138), multiple myeloma (Ozaki et al., 1997, Blood 90: 3179-3186; Tsunenati et al., 1997, Blood 90: 2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res 52: 2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J Immunother Emphasis Tumor Immunol 19: 93-101), leukemia (Zhong et al., 1996, Leuk Res 20: 581-589), colorectal cancer (Moun et al., 1994, Cancer Res 54:

6160-6166); Velders et al., 1995, Cancer Res 55: 4398-4403), and breast cancer (Shepard et al., 1991, J Clin Immunol 11: 117-127).

In the practice of a method of the invention, antibodies specific for kallikrein polypeptides capable of inhibiting the growth of cancer cells expressing kallikrein polypeptides are administered in a therapeutically effective amount to cancer patients whose tumors express or overexpress kallikrein polypeptides. The invention may provide a specific, effective and long-needed treatment for renal cell carcinoma. The antibody therapy methods of the invention may be combined with other therapies including chemotherapy and radiation.

Patients may be evaluated for the presence and levels of kallikrein polypeptides expression and overexpression in tumors, preferably using immunohistochemical assessments of tumor tissue, quantitative imaging as described herein, or other techniques capable of reliably indicating the presence and degree of expression of kallikrein polypeptides. Immunohistochemical analysis of tumor biopsies or surgical specimens may be employed for this purpose.

Antibodies specific for kallikrein polypeptides useful in treating cancer include those that are capable of initiating a potent immune response against the tumor and those that are capable of direct cytotoxicity. In this regard, the antibodies may elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites or complement proteins. In addition, antibodies specific for kallikrein polypeptides that exert a direct biological effect on tumor growth are useful in the practice of the invention. Such antibodies may not require the complete immunoglobulin to exert the effect. Potential mechanisms by which such directly cytotoxic antibodies may act include inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism by which a particular antibody exerts an anti-tumor effect may be evaluated using any number of *in vitro* assays designed to determine ADCC, antibody-dependent macrophage-mediated cytotoxicity (ADMMC), complement-mediated cell lysis, and others known in the art.

The anti-tumor activity of a combination of antibodies specific for kallikrein polypeptides may be evaluated *in vivo* using a suitable animal model. Xenogenic cancer models, wherein human cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice, may be employed.

The methods of the invention contemplate the administration of combinations, or "cocktails" of different individual antibodies recognizing epitopes of kallikrein polypeptides. Such cocktails may have certain advantages inasmuch as they contain antibodies that bind to different epitopes and/or exploit different effector mechanisms or combine directly cytotoxic antibodies with antibodies that rely on immune effector functionality. Such antibodies in combination may exhibit synergistic therapeutic effects. In addition, the administration of the antibodies may be combined with other therapeutic agents, including but not limited to chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL2, GM-CSF). The antibodies may be administered in their "naked" or unconjugated form, or may have therapeutic agents conjugated to them.

- 27 -

The antibodies specific for kallikrein polypeptides used in the practice of the method of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material which when combined with the antibodies retains the anti-tumor function of the antibodies and is non-reactive with the subject's immune systems. Examples
5 include any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16^{sup}.th Edition, A. Osal., Ed., 1980).

Antibody formulations may be administered via any route capable of delivering the antibodies to the tumor site. Routes of administration include, but are not limited to, intravenous, intraperitoneal,
10 intramuscular, intratumor, intradermal, and the like. Preferably, the route of administration is by intravenous injection. Antibody preparations may be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.

Treatment will generally involve the repeated administration of the antibody preparation via an acceptable route of administration such as intravenous injection (IV), at an effective dose. Dosages will
15 depend upon various factors generally appreciated by those of skill in the art, including the type of cancer and the severity, grade, or stage of the cancer, the binding affinity and half life of the antibodies used, the degree of expression of kallikrein polypeptides in the patient, the extent of circulating kallikrein polypeptide antigens the desired steady-state antibody concentration level, frequency of treatment, and the influence of
20 any chemotherapeutic agents used in combination with a treatment method of the invention.

Daily doses may range from about 0.1 to 100 mg/kg. Doses in the range of 10-500 mg antibodies per week may be effective and well tolerated, although even higher weekly doses may be appropriate and/or well tolerated. A determining factor in defining the appropriate dose is the amount of antibodies necessary to be therapeutically effective in a particular context. Repeated administrations may be required to achieve
25 tumor inhibition or regression. Direct administration of antibodies specific for kallikrein polypeptides is also possible and may have advantages in certain situations.

Patients may be evaluated for kallikrein polypeptides, preferably in serum, in order to assist in the determination of the most effective dosing regimen and related factors. The assay methods described herein, or similar assays, may be used for quantitating circulating kallikrein polypeptide levels in patients prior to
30 treatment. Such assays may also be used for monitoring throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters, such as serum kallikrein polypeptides.

The invention further provides vaccines formulated to contain kallikrein polypeptides or fragments thereof. The use in anti-cancer therapy of tumor antigens in a vaccine for generating humoral and cell-mediated immunity is well known and, for example, has been employed in prostate cancer using human
35 PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63: 231-237; Fong et al., 1997, J. Immunol. 159: 3113-3117). These methods can be practiced by employing kallikrein polypeptides, or fragments thereof, or polynucleotides and recombinant vectors capable of expressing and appropriately presenting the kallikrein immunogens.

By way of example, viral gene delivery systems may be used to deliver polynucleotides encoding kallikrein polypeptides. Various viral gene delivery systems which can be used in the practice of this aspect of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbus virus (Restifo, 1996, Curr. Opin. Immunol. 8: 658-663). Non-viral delivery systems may also be employed by using naked DNA encoding kallikrein polypeptides, or fragments thereof introduced into the patient (e.g., intramuscularly) to induce an anti-tumor response.

Various *ex vivo* strategies may also be employed. One approach involves the use of cells to present kallikrein antigens to a patient's immune system. For example, autologous dendritic cells which express MHC class I and II, may be pulsed with kallikrein polypeptides, or peptides thereof that are capable of binding to MHC molecules, to thereby stimulate renal cell carcinoma patients' immune systems (See, for example, Tjoa et al., 1996, Prostate 28: 65-69; Murphy et al., 1996, Prostate 29: 371-380).

Anti-idiotypic antibodies specific for kallikrein polypeptides can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing the polypeptides. The generation of anti-idiotypic antibodies is well known in the art and can readily be adapted to generate anti-idiotypic antibodies that mimic an epitope on a kallikrein polypeptide (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J Clin Invest 96: 334-342; Herlyn et al., 1996, Cancer Immunol Immunother 43: 65-76). Such antibodies can be used in anti-idiotypic therapy as presently practiced with other anti-idiotypic antibodies directed against tumor antigens.

Genetic immunization methods may be utilized to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing kallikrein polypeptides. Constructs comprising DNA encoding kallikrein polypeptides/immunogens and appropriate regulatory sequences may be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded kallikrein polypeptides/immunogens. The polypeptides/immunogens may be expressed as cell surface proteins or be secreted. Expression of the polypeptides/immunogens results in the generation of prophylactic or therapeutic humoral and cellular immunity against the cancer. Various prophylactic and therapeutic genetic immunization techniques known in the art may be used.

The invention further provides methods for inhibiting cellular activity (e.g., cell proliferation, activation, or propagation) of a cell expressing kallikrein polypeptides. This method comprises reacting immunoconjugates of the invention (e.g., a heterogeneous or homogenous mixture) with the cell so that the kallikrein polypeptides form a complex with the immunoconjugates. A subject with a neoplastic or preneoplastic condition can be treated when the inhibition of cellular activity results in cell death.

In another aspect, the invention provides methods for selectively inhibiting a cell expressing kallikrein polypeptides by reacting a combination of the immunoconjugates of the invention with the cell in an amount sufficient to inhibit the cell. Amounts include those that are sufficient to kill the cell or sufficient to inhibit cell growth or proliferation.

Vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used to deliver polynucleotides encoding kallikrein polypeptides to a targeted organ, tissue, or cell population. Methods well known to those skilled in the art may be used to construct

recombinant vectors that will express antisense nucleic acid molecules for kallikrein polypeptides. (See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra)).

Genes encoding kallikrein polypeptides can be turned off by transfecting a cell or tissue with vectors that express high levels of a desired kallikrein polypeptide-encoding fragments. Such constructs can inundate cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases.

Modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the regulatory regions of genes encoding kallikrein polypeptides, i.e., the promoters, enhancers, and introns. Preferably, oligonucleotides are derived from the transcription initiation site, e.g. between -10 and +10 regions of the leader sequence. The antisense molecules may also be designed so that they block translation of mRNA by preventing the transcript from binding to ribosomes. Inhibition may also be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Therapeutic advances using triplex DNA were reviewed by Gee J E et al (In: Huber B E and B I Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco N.Y.).

Ribozymes are enzymatic RNA molecules that catalyze the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. The invention therefore contemplates engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding kallikrein polypeptides.

Specific ribozyme cleavage sites within any potential RNA target may initially be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once the sites are identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be determined by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Methods for introducing vectors into cells or tissues include those methods discussed herein and which are suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors may be introduced into stem cells obtained from a patient and clonally propagated for autologous transplant into the same patient (See U.S. Pat. Nos. 5,399,493 and 5,437,994). Delivery by transfection and by liposome are well known in the art.

Kallikrein polypeptides and polynucleotides encoding the polypeptides, and fragments thereof, antibodies, and/or agents identified using a method of the invention, or combinations thereof, may be used in the treatment of renal cell carcinoma or diseases, conditions or syndromes associated with renal cell carcinoma, in a subject. The kallikrein polypeptides, polynucleotides, and agents may be formulated into compositions for administration to subjects suffering from renal cell carcinoma. Therefore, the present invention also relates to a composition comprising kallikrein polypeptides, or polynucleotides encoding the

- 30 -

polypeptides, or a fragment thereof, or an agent identified using a method of the invention, and a pharmaceutically acceptable carrier, excipient or diluent. A method for treating or preventing renal cell carcinoma in a subject is also provided comprising administering to a patient in need thereof, kallikrein polypeptides, or polynucleotides encoding the polypeptides, an agent identified in accordance with a method
5 of the invention, or a composition of the invention.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the substance from the action of enzymes, acids and other natural conditions that may inactivate the
10 substance.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's
15 Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the active substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The compositions are indicated as therapeutic agents either alone or in conjunction with other
20 therapeutic agents or other forms of treatment (e.g. chemotherapy or radiotherapy). The compositions of the invention may be administered concurrently, separately, or sequentially with other therapeutic agents or therapies.

The following non-limiting examples are illustrative of the present invention:

Example 1

25 Human kallikreins 5, 6, 10, and 11 (hK5,6/10/11) are expressed by many normal tissues and it has been suggested that they may represent candidate cancer diagnostic/prognostic markers. Renal cell carcinoma (RCC) is characterized by unpredictable outcome, despite the use of conventional prognostic factors. The immunohistochemical expression (IE) and the predictive value of the above kallikreins was evaluated in RCC. Included in the study were 95 patients who underwent radical nephrectomy for RCC. The
30 median follow-up was 60 (1-180) months. Fifty seven of the 95 RCC cases were immunostained for hK5, 70/95 for hK6, 70/95 for hK10, and 69/95 for hK11, respectively. The immunohistochemical method of streptavidin-biotin-peroxidase using anti-hK5, /6/10/11 monoclonal and polyclonal antibodies was performed. The IE of all kallikreins was correlated with tumor size, histological type, histological malignancy, mitotic index, and pathological stage. The Fuhrman 4-scale grading system was used for the
35 determination of the histological malignancy. For statistical analysis, four grades were collapsed into two and RCC cases were categorized as low and high malignant (LM and HM) respectively. Statistical analysis included Pearson Chi-square and Kruskal Wallis tests. Survival data were analyzed using Kaplan-Meier and Cox regression analysis. A Pvalue < 0.05 was considered significant. In the normal (adjacent to tumor) renal parenchyma, the epithelium of the urinary tubuli showed a cytoplasmic IE of all kallikreins. In RCC, their IE

- 31 -

was decreased: 33/57 cases (58%) were positive for hK5, 27/70 (39%) for hK6, 46/70 (66%) for hK10 and 32/69 (46%) for hK11, respectively. A statistically significant positive correlation was observed among the IE of all kallikreins. HM-RCC expressed all kallikreins in a higher percentage than LM-RCC, but a statistically significant difference was observed only in the case of hK6 and hK10 (55% vs. 27%, $p=0.016$ and 79% vs. 56%, $p=0.044$ respectively). Hk6 and hK11 showed a positive correlation with pathological stage: hK6 with both Robson and TNM 1997 staging systems ($p=0.010$ and $p=0.017$ respectively), and hK11 only with the Robson staging system ($p=0.045$). In both the Kaplan-Meier and the univariate Cox regression analysis, hK6 IE showed a negative correlation with disease survival ($p=0.05$ and $p=0.038$ respectively). In univariate analysis, nuclear grade, Robson and TNM staging systems correlated with disease survival as well. However, in the multivariate analysis, TNM staging system was the only independent prognostic factor. In conclusion, although the IE of hK5/6/10/11 is down-regulated in RCC, tumors of high grade and/or advanced stage express one or more of the above kallikreins in a higher percentage. It seems that hK6 may significantly contribute to information in predicting poor disease outcome for RCC.

The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the domains, cell lines, vectors, methodologies etc. which are reported therein which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Below full citations are set out for the references referred to in the specification.

Table 1

Kallikrein Polypeptide	Kallikrein Nucleic Acid Designation	GenBank Accession No.
Kallikrein 5	KLK5	AAF03101, AF135028 (mRNA join 2101..2131, 2210..2293, 4762..5023, 5763..6019, 6105..6238, 11092..11570) (CDS join 2221..2293, 4762..5023, 5763..6019, 6105..6238, 11092..11247), AF168768 (CDS 170..1051)
Kallikrein 6	KLK6	AFB66483, AF013988 (CDS 174..881), AF149289 (CDS 3567..3606, 4346..4502, 8211..8369, 9791..9927, 11805..11954) (mRNA join 2001..2185, 3084..3135, 3559..3606, 4346..4502, 8122..8369, 9791..9927, 11805..11957), HSU62801 (CDS 246..980)
Kallikrein 10	KLK10	AAC14266, AF055481 (CDS 614..701, 2455..2635, 3589..3863, 4195..4328, 4793..4945) (mRNA join 48..120, 605..701, 2455..2635, 3589..3863, 4195..4328, 4793..5474), NM_002776 (CDS 220..1050)
Kallikrein 11	KLK11	BAA33404, AAD47815, AB012917 (CDS 26..874), AF164623 (CDS 4224..4263, 5061..5217, 5545..5810, 6627..6727..6763, 7158..7307) (mRNA join 2312..2398, 4189..4263, 5061..5217, 5545..5810, 6627..6763, 7158..7310)

We Claim:

1. A method for detecting kallikrein polypeptides or polynucleotides encoding kallikrein polypeptides that are associated with renal cell carcinoma in a patient comprising:
 - 5 (a) taking a sample from a patient;
 - (b) detecting or identifying in the sample one or more kallikrein polypeptides or polynucleotides encoding the kallikrein polypeptides wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 ; and
 - 10 (c) comparing the detected amount with an amount detected for a standard.
2. A method for detecting kallikrein polypeptides associated with renal cell carcinoma in a patient comprising:
 - (a) obtaining a sample from a patient;
 - 15 (b) detecting in the sample one or more kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
 - (c) comparing the detected amounts with amounts detected for a standard.
3. A method for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting in a sample from the subject one or more kallikrein polypeptides, wherein the kallikrein polypeptides
20 comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein.
4. A method as claimed in claim 1, 2 or 3 wherein the kallikrein polypeptides are detected using antibodies that bind to the kallikrein polypeptides or parts thereof
5. A method of detecting renal cell carcinoma in a patient, the method comprising comparing:
 - 25 (a) levels of kallikrein polypeptides in a sample from the patient, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
 - (b) normal levels of expression of the kallikrein polypeptides in a control sample, wherein a significant difference in levels of kallikrein polypeptides, relative to the corresponding
30 normal levels, is indicative of renal cell carcinoma.
6. A method of any proceeding claim where the levels of kallikrein polypeptides are higher than normal levels and are indicative of advance disease and/or poor prognosis.
7. A method for monitoring the progression of renal cell carcinoma in a patient, the method comprising: (a) detecting in a sample from the patient at a first time point, kallikrein polypeptides,
35 wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; (b) repeating step (a) at a subsequent point in time; and (c) comparing levels detected in steps (a) and (b), and thereby monitoring the progression of renal cell carcinoma.

- 34 -

8. A method for determining in a patient whether renal cell carcinoma has metastasized or is likely to metastasize in the future, the method comprising comparing (a) levels of kallikrein polypeptides, in a patient sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) normal levels or non-metastatic levels of the kallikrein polypeptides, in a control sample wherein a significant difference between the levels of expression in the patient sample and the normal levels or non-metastatic levels is an indication that the renal cell carcinoma has metastasized.
9. A method for assessing the aggressiveness or indolence of renal cell carcinoma comprising comparing: (a) levels of expression of kallikrein polypeptides, in a patient sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) normal levels of expression of the kallikrein polypeptides, in a control sample, wherein a significant difference between the levels in the patient sample and normal levels is an indication that the cancer is aggressive or indolent.
10. A method for diagnosing and monitoring renal cell carcinoma in a sample from a subject comprising isolating polynucleotides from the sample, and detecting in the sample polynucleotides encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein.
11. A method as claimed in claim 10 wherein significant differences in the levels of the polynucleotides in the sample compared to a control is indicative of disease, disease stage, stage, and/or prognosis.
12. A method for determining the presence or absence of renal cell carcinoma in a subject comprising: (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides encoding kallikrein polypeptides relative to a predetermined cut-off value, and therefrom determining the presence or absence of renal cell carcinoma in the subject.
13. A method as claimed in claim 12, wherein the nucleic acids are mRNA and the levels of nucleic acids are detected by polymerase chain reaction.
14. A method as claimed in claim 12, wherein the nucleic acids are mRNA and the amounts of mRNA are detected using a hybridization technique, employing oligonucleotide probes that hybridize to kallikrein polypeptides.
15. A method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, the method comprising comparing: (a) levels of kallikrein polypeptides, and/or polynucleotides encoding same in a first sample obtained from a patient and exposed to the test agent, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein polypeptides and/or polynucleotides encoding same in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of the kallikrein polypeptides and/or polynucleotides encoding same in the first sample,

relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting renal cell carcinoma in the patient.

16. A method of claim 15 wherein the first and second samples are portions of a single sample obtained from the patient.
- 5 17. A method of claim 15 wherein the first and second samples are portions of pooled samples obtained from the patient.
18. A method of assessing the efficacy of a therapy for inhibiting renal cell carcinoma in a patient, the method comprising comparing: (a) levels of kallikrein polypeptides and/or polynucleotides encoding same in a first sample obtained from the patient, wherein the kallikrein polypeptides
10 comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein polypeptides and/or polynucleotides encoding same in a second sample obtained from the patient following therapy, wherein a significant difference in the levels of expression of the kallikrein polypeptides and/or polynucleotides in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting renal cell carcinoma in the patient.
- 15 19. A method of selecting an agent for inhibiting renal cell carcinoma in a patient the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately exposing aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of kallikrein polypeptides and/or polynucleotides encoding same in each of the aliquots, wherein the kallikrein
20 polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (d) selecting one of the test agents which alters the levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.
- 25 20. A method of inhibiting renal cell carcinoma in a patient, the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of kallikrein polypeptides and/or polynucleotides encoding same in each of the aliquots, wherein the kallikrein polypeptides
30 comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (d) administering to the patient at least one of the test agents which alters the levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.
- 35 21. A method of assessing the renal cell carcinoma cell carcinogenic potential of a test compound, the method comprising: (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and (b) comparing expression of kallikrein polypeptides and/or polynucleotides encoding same, in each of the aliquots, wherein the kallikrein polypeptides
comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and wherein a significant difference in levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot maintained in the presence of the test compound,

- 36 -

relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses renal cell carcinoma cell carcinogenic potential.

22. An *in vivo* method for imaging renal cell carcinoma comprising:
 - (a) injecting a patient with agents that bind to kallikrein polypeptides, the agents carrying labels for imaging the renal cell carcinoma, and wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11;
 - (b) allowing the agents to incubate *in vivo* and bind to the kallikrein polypeptides; and
 - (c) detecting the presence of the labels localized to the renal cell carcinoma.
23. A method of inhibiting renal cell carcinoma in a patient at risk for developing renal cell carcinoma, the method comprising inhibiting expression of genes encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11.
24. A method of any preceding claim comprising at least two of the kallikrein polypeptides.
25. A method of any preceding claim comprising at least three of the kallikrein polypeptides.
26. A method of claim 22 where the kallikrein polypeptides are kallikrein 6 and kallikrein 11.
27. A method of any preceding claim wherein the patient sample comprises serum obtained from the patient.
28. A kit for carrying out a method as claimed in any preceding claim.
29. A kit for assessing whether a patient is afflicted with renal cell carcinoma, the kit comprising reagents that specifically bind with kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.
30. A kit for assessing the suitability of each of a plurality of agents for inhibiting renal cell carcinoma in a patient, the kit comprising: (a) the plurality of agents; and (b) reagents for detecting kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.
31. A kit as claimed in claim 28 or 29 wherein the reagents are antibodies that specifically bind with protein or protein fragments corresponding to kallikrein polypeptides.

Sequence Listing

SEQ ID NO. 1

hk5 amino acid

5

MATARPPWMWVLCALITALLLGVTEHVLANNVSCDHPSNTVPSPGSNQDLGAGAGEDARSDDSSSRIINGSD
 CDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAHCRKKVFRVRLGHYSLSPVYESGQMFQGVKSIPHPG
 YSHPGHSNDLMLIKLNRRIKPTKDVRIPIVSSHCPASAGTKCLVSGWGTTKSPQVHFVKVLQCLNISVLSQKR
 CEDAYPRQIDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCAREPNRPGVYINLCKFTKWIQET
 IQANS

10

SEQ ID NO. 2

KLK5 CDS

ggtgtctgtg cgtcctgcac ccacatcttt ctctgtcccc tccttgccct gctcggaggg
 15 tgctagactc ctatcttctg aattctatag tgcctgggtc tcagcgagc gccgatgggtg
 gcccgctcct gtggttcctc tctacttggg gaaatcaggt gcagcgcca tggctacagc
 aagaccccc tggatgtggg tgctctgtgc tctgatcaca gccttgcttc tgggggtcac
 agagcatgtt ctgccaaca atgatgttct ctgtgaccac cctctaaca ccgtgccctc
 tgggagcaac caggacctgg gagctggggc cggggaagac gcccggtcgg atgacagcag
 20 cagccgcatc atcaatggat ccgactgcga tatgcacacc cagccgtggc aggccgagct
 gttgctaagg cccaaccagc tctactcggg gccggtgttg gtgcatccac agtggctgct
 cagggccgcc cactgcagga agaaagtctt cagagtccgt ctcgccact actccctgtc
 accagtttat gaatctgggc agcagatgtt ccagggggtc aaatccatcc cccaccctgg
 ctactccac cctggccact ctaacgacct catgctcatc aaactgaaca gaagaattcg
 25 tcccactaaa gatgtcagac ccatcaacgt ctctctcatc tgtccctctg ctgggacaaa
 gtgcttggtg tctggctggg ggacaaccaa gagccccaa gtgcacttcc ctaaggtcct
 ccagtgttg aatatcagcg tgctaagtca gaaaagggtc gaggatgctt acccgagaca
 gatagatgac accatgttct gcgcccgtga caaagcaggt agagactcct gccagggtga
 ttctgggggg cctgtggtct gcaatggctc cctgcaggga ctctgtctct ggggagatta
 30 cccttctgcc cggcccaaca gaccgggtgt ctacacgaac ctctgcaagt tcccaagt
 gatccaggaa accatccagg ccaactcctg agtcatcca ggactcagca caccggcatc
 cccacctgct gcagggacag ccctgacact cctttcagac cctattcct tccagagat
 gttgagaatg ttcattctctc cagccctga ccccatgtct cctggactca ggtctgtctt
 cccccacatt gggctgaccg tgtctctcta gttgaaccct gggaacaatt tccaaactg
 35 tccagggcgg ggggtgcgtc tcaatctccc tggggcactt tcatcctcaa gctcagggcc
 catcccttct ctgcagctct gacccaaatt tagtcccaga aataaactga gaagtggaaa
 aaaaaaa

40 SEQ ID NO. 3

KLK5 nucleic acid

gggcccagag tgaaggcaag agaaggagtt gagagctccc tctgcaaagt ggcttgagtc
 tcccctgcct aaaatgcagg gagagggagg cagaaagaca ggaagagga aggggtgggg
 45 aagaaagaga gagagagaga gagacagaat aacacaacta cagaaacaca gagagaacac
 acagagagcc tgggacacag ggacacacag agtcagagag aaaagagaag atagagaaag
 acacaaatgg agacacagag gtgtaaaaga agagagatta acagagtccc agatacacgc
 aaaggggcag aagcacagtt ttcagggtgg tgtctatgat catcttcttt tttttttttt
 tttttttttt tttttgagac ggagtctcgc tctgtcgcgc aggttgaggt gcagtggcgg
 50 gatctcggct cactgcaagc tccgcctccc gggttcacgc cattctcctg cctcagcctc
 ccaagttagct gggactacag gcgcccgcga ctacgcccgg ctaatttttt tgtattttta
 gttagagcgg ggtttcaccg ttttagccgg gatggcctcg atctcctgac cctgtgatcc
 gccgcctcgg gctcccaaaa gtgctgggat tacaggcgtg agccaccgag cccggccatg
 atcatcttct tgactatgct gatgtgacaa gtacctaaag ccatcagact ctacccttta
 55 aatatgcagt ttgggccagg caccgtggct catgcctgta attccagcac tttgggaggc
 agagggtggg gaatcacttg aggccaggag tttgagacca gcctggccaa catggtgaaa

	ctctgtccttt	actaaaaaaaa	aaaaaaaaaaa	aaaaaaaaaatc	agccgggtgt	cgtggggcac
	acctgtaatc	ccagctatgc	tggaggctga	ggcacgagag	tcacttgaac	cctggaggcg
	gagggttgacg	tgggccgaga	tcacatcacc	gccctccagc	ctgggcgaca	gagcaagact
	ctgtctcaaa	taaataaata	aacaaacgaa	caagcagttt	gtgttacctt	agttatatct
5	aaaaaaaaaaa	tgctgtcaac	aaatagagca	gaagtgaat	aaaggaaaat	aaatgggcca
	agaactctaa	ggtatatgtt	acaaatcatt	cagaaccttt	aaaaaagaaa	gaatcacaga
	ggcatagaaa	gacagggagg	aacagggaga	cagaaacacc	tgtggcccaa	ggagaacaaa
	acaaggctcc	taagacagac	aggaggagag	agagagagag	tgagtgaag	acagacagag
	aaaaagacag	agagagagag	acagagacag	agagacagag	aggcgagagg	gatagaaaga
10	gagagagggg	tggagagaga	cacgagatat	tgagagagac	tcagaaagat	agccgagggg
	gaaccacaga	gagatggaag	aagactctga	gaaaaaacca	gagacaaaga	tggaaagagg
	agtatcgagg	gtgaacagac	agtgttgaa	tgagcaaat	gcagagaaga	aagcaagcaa
	tcaggcgcc	aagaatagtg	acccagagtt	ggtgagaagc	cagatcctta	aggctggggg
	aggcagggaa	ggggctggcc	tggcttccgg	agacccctcc	ccattctccg	ggccagggag
15	gtaggagtg	acattccgga	ctgggtgggg	ggtgctctgg	gggtggagat	agggggagca
	ggaggagcta	ttgctaaggc	ccgataggca	cctcattgcc	cggaatgtg	ccccagggag
	cagtgggtgg	ttataactca	ggcccgtg	ccagagccca	ggaggaggca	gtggccaggga
	aggcacaggc	ctgagaagtc	tgcggctgag	ctgggagcaa	atccccacc	ccctacctgg
	gggacagggc	aagtgaagcc	tgtgagggg	ggctcagcag	gcagggaagg	agagggtgtc
20	gtgcgtcctg	caccacatc	tttctctgtc	ccctccttgc	cctgtctgga	ggctgctaga
	ctcctatctt	ctgaattcta	tagtgccctg	gtctcagcgc	agtgcctatg	gtggcccgtc
	cttgtgggtc	ctctctacct	ggggaaataa	ggtaggggag	ggaggggaaag	tgggttaagg
	gtcccccga	tgcctggggc	ctcccaacc	tctgacattc	cccatccagg	tcagcggcc
	atggctacag	caagaccccc	ctggatgtgg	gtgctctgtg	ctctgatcac	agccttgctt
25	ctgggggtca	caggtaacca	gaactctggg	gtgggagggg	tgtgggattg	ggaggactgt
	ctctgcggca	ctagagcgcc	tgtcccctgg	ggaactgtgt	gagcctgggc	atgactccgg
	gaccgggtga	atgtgagctc	ctgtctgtac	ttgtggttgt	gcgatcgtat	gtggccctgt
	gactgccacg	gtgtgtgtcg	gggaggggga	tgccttttcc	catatcaggt	gactgtgcgg
	caggtggcac	tgaccctttg	aggctgtgtg	tgtggttttg	tgattgtgtg	tgcatttaag
30	attgtgtgtg	gctccacagc	tgtgtgggtg	aatgcatgta	gcactggggg	tgttactgt
	gtgtttggct	gtgtgtgggtg	acttggcatt	gtatatgact	gcaggatatc	gcagttcctg
	tccctgaggt	cccgggattg	cgtgcaacaa	aagtgtcat	caccatggaa	agctgtgact
	gtgtgctgct	tgcaggcgat	tatgtgattg	tggctgagtg	tgacgttatg	gatgcccgtg
35	ttgtgaccg	tgtgactacc	tgaagctctg	tgtaggggtg	actgtatgtg	actgtgtgtg
	tctgtgtgag	gccgtgtaaa	tgctactgta	tgtgtgatgg	tcagactgtg	tgtctggagt
	ttctgtctct	gcctggaggg	atagaggggtg	caggggtagc	tatctctggg	agatgggtgc
	caggtgactg	acttgacagt	tgtgcctgtg	tgacagaagag	tatgtggcag	tctgaacatc
	tgtgcacaca	cggcatctgt	gcgtggcact	gagacactgt	ggatgagggg	gtgcgatccc
	gtaggctgc	ccgggagcgt	gtgtacctgg	agacagagct	gtatgttagc	tgacactgtg
40	gaggcaacat	gggcgtgtct	gcagaactgc	gtgcgtgctt	ggctgttact	ctgtgtgtgc
	gcgtggttct	tgggggtgag	tctgtaatga	tgggtgtgcc	agggccatca	gcaagggtaa
	gaaccaggcc	gggcgcggtg	gctcacgcct	gtaatcccag	ccctttggga	ggccgaggca
	ggcggtacac	ctgaggtcgg	gagatcgagg	ccagcctgac	caacatggag	aacccgtct
	ctactaaaaa	tacaaaaaat	tagctggtgt	ggtggcgctg	gcctgtaatc	ccagctactc
45	gggagactgg	ggcagaaaaa	tcgcttgaac	ccgggaggtg	gagggttgcg	tgagccgaga
	tgcgcgcatt	gcactccagc	ctgggcaaca	agagcgaaac	tccgtctcga	aagaaaaaaa
	gaaaaaaaaa	agggtgaaga	ccagtgaatg	ggcacgggag	gactgatgat	ggagtggggc
	atgcatgtag	tctgtaggtc	tgtgtgtgag	aggaggagat	tgacaggatt	gagaaggcat
	gttttcatct	gagaattcag	aaacctaggc	ctgctcttcc	cctccatgtg	gccccctaag
50	ctgagccctt	ctttcctggg	cctgctttcg	gaaccctagc	tccgcccattg	agctctgacc
	ccacctcctt	tcctcaacca	cgcccttagg	ccagactcta	gtggaccccg	cctaaggcca
	caccocctttg	ggccaggctc	caccccttat	tctgtgggta	ccttctagaa	ccccctcaa
	agtcagagct	tttttttttt	tttttttgga	gacagtcttg	ctctctctcc	caggctggag
	tgagtggtgc	tgatctcggc	tactgcaac	ctctgcctcc	caggttcaag	tgattctcgt
55	gctccacact	cctgagtagc	tgggattaca	ggtgcgcgcg	accacgcctg	gctaattttt
	gtctcttttag	tagagacagg	gtttcacctt	gttgccagg	ctggtctcaa	actcccaacc
	tcaggtgatc	cgccacctc	ggcctcccag	agtgtctggg	ttacaggcgt	gagccaccgc
	cccagccca	aagtcagagc	tctttatagg	agactctaac	atgtaaccct	gaccctggcc
	ctaactaagt	caattccaaa	ccccttccgt	cctccagccc	tgacccact	cactgagggc

	tgacccact	tottgagacc	agttccatcc	ctaaagccct	ggtctccctc	ccatccccag
	gtctcagccc	ccacagcttt	ggcactaccc	ctgagcttgt	ccaggaatcc	tgtacccaat
	tttaccctca	catgtagttc	tagccaattc	caggaatctg	tgaggtccag	ttagagttcca
	gtaaccctac	ctgagcctgg	gctctgtcct	tgagcttgag	cctgggcttg	agaggtgcca
5	ctcttattct	ccaggccctg	cccctgcccc	ctcagcatgt	cagacaccca	ccctctagct
	ggtctggcct	cttgagtctg	aaacccaccc	ccagcccaag	ccccgcctct	gagccccgcc
	caacccattt	tccgttccca	gagcatgttc	tcgccaacaa	tgatgtttcc	tgtgaccacc
	cctctaacac	cgtgccctct	gggagcaacc	aggacctggg	agctggggcc	ggggaagacg
	cccggctcga	tgacagcagc	agccgcacac	tcaatggatc	cgactgcgat	atgcacaccc
10	agcctgggca	ggccgcgctg	ttgctaaggc	ccaaccagct	ctactgcggg	gcggtgttgg
	tgcatccaca	gtggctgctc	acggccgccc	actgcaggaa	gaagtgagtg	ggagtccaa
	gaggagggtt	ggtggggacg	gggaagtggg	ggtgggggtg	gggaagtggg	ggtgggggtg
	tcatggaggt	gagggctggt	ggggacgggg	aagtggggtt	gggggtgtca	tggaaagtga
	gggttggttg	ggatgggttg	gggatgtggg	agcaggagga	ggtcagagtg	gggataggac
15	taaggatgga	gttttgccgg	ggagcaaggt	gggaggatga	ggttgagag	gggagagtgt
	tgtggttagg	aatgggaagg	agccaaggat	gggttggatt	tggggtagg	agcatatatt
	tgttgaatgg	tttgggatgg	aggtggaatt	gggatgtgct	ttagaattgg	gggtgggtga
	aaatcggtct	ggggtggaaa	tgaagatagc	atggagatag	ggttgagatt	gggagcagat
	atagaatgaa	ggatgggat	tggagttttg	ggtggggttg	gagatggttg	gatttgggct
20	tgagaatgca	tatggtgatg	gcttctgggt	agggaaagaa	ttagggttgg	gaatgggatg
	ggtttggaat	tgtgactggg	atggggacag	gcatgggatt	ggagaccaag	agggagttag
	ggatgggttg	gggaccgggg	gtggggatgg	gggtggggct	ggggctgggt	gtggggttgg
	gattggcggt	ggacgtggag	atagagatca	gggttgggtg	tgacctgccc	catcttcctc
	agagttttca	gagtcggtct	cggccactac	tccctgtcac	cagtttatga	atctgggcag
25	cagatgttcc	aggggtcaaa	atccatcccc	cacctgggct	actcccaccc	tggccactct
	aacgacctca	tgctcatcaa	actgaacaga	agaattcgct	ccactaaaga	tgtcagaccc
	atcaacgtct	cctctcattg	tccctctgct	gggacaaagt	gcttggtgtc	tggctggggg
	acaaccaaga	gcccccaagg	tgagtgtcca	ggttcttctt	gataccgacc	catctctgcc
	gctttccatc	tttctccact	tctcattgtg	ttcctgtttg	acagtgcact	ctctaaggct
30	cctccagtcg	ttgaatatca	cgctgctaag	tcagaaaagg	tgcgaggatg	cttaccggag
	acagatagat	gacaccatgt	tctgcgccgg	tgacaaagca	ggtagagact	cctgccaggt
	gaggacacct	ctctttattc	agcagatata	cactgagtgc	caactcggta	acatggagcg
	ttgccaattt	ctgagaatcc	agcaattgcc	aagacagtca	ggacccctgt	tctcacagag
	ctcataccct	agagtagtgg	tgtttagtag	aaataatgct	gagctgctta	tgtcatttcc
35	agttttttag	tagccacatt	aaaacaggta	aaaaaggctg	ggcgagtggt	ctcacacctg
	taatcccagc	actttgggag	gctgaggcag	gcagatcacc	tttggtcagg	agtttgagac
	tagcctggcc	aacatggcga	aactctgtct	ctaaaaaaa	atacaaaaat	tagcctggca
	tgggtggcgg	cgcctgtaat	ctcagctgct	caggaggccg	agacacaaga	atcacttaaa
	cccaggaggt	ggaggttgca	gtgagctgag	atcgtgccac	tcactccaac	ctggggagaca
40	gagtgacact	tttgtctcaa	aaagaaaaaa	aaaaacaagt	aaaaaagaaa	caggtgaaat
	taactttaat	aacccaatgt	atcccaaata	caatcatttc	aaagtgtaat	taataataaa
	caattatgaa	tgagatactt	tacattcttt	tcttgttttc	atattaagtc	tttgaagtgt
	agtatatatg	ttatgctgac	agcacatctc	aatttggact	agctacattt	caggtgctca
	gtagccacat	gtggctagca	gttactgtat	tggtatggac	ggatctagag	ggaaaatata
45	gggctgtttt	gtatggttgg	gcagggttgg	cactgcataa	agataccata	tctaattagg
	gcactccgtg	ttacagatgt	cagttttggc	agttttcagg	cgtgtggtag	ttaatgtgtc
	tgtttcaaca	aaatctgtaa	tatgacagtt	ttctagcaag	tgctggtaaa	atatcttgag
	gaaggaaaa	agaaatctgg	taggtatttt	tacaagagaa	tatttaatac	aggggattaa
	ttgcaaagct	gctggaagg	ctggagggaac	aaagttaaaa	aataaaaaac	tctgtggtca
50	agaatctgca	taaatagggc	aatttcagag	agtgttaag	gttaaccca	aaataaaaca
	tggtttttag	atagtaaaca	ataaggcca	atattcaaaa	aggtggtcag	gggagcctcc
	ttggagaggt	ggcatttgag	cagagaatgg	atgacacaaa	gaagctaaac	tcgtgaagtt
	taaggggaaa	gaaaaggcac	gtgcaaggc	cctgaggcag	taaggaattt	ggctgattca
	aagaagaaga	ggaaaccaat	gcaactggag	aacaaaagt	ggggcaacag	tagaaagtga
55	cgctggaggt	gtaggcagg	gcgaatgctc	tgcaagtatt	tcttggtcac	caacacagag
	cttcctatg	ttctaattga	agctgtatct	gttgaggaa	acagaattta	aaatcaaaact
	gttacatcaa	ccagcacctc	tctctgtatt	caggctccca	agggatctag	aaggacgtaa
	gttaacaagc	tctcattagc	aggggtgtgt	tttcaacagt	agttaggaag	ctggggattc
	aggagtactc	cagtcctcat	gctatgaaaa	gctcccccca	aattgtacaa	acctgacaaa

tgcaacacct cccagctct cccatttct tctctgtgcc ctgggtgtgg ggggtgggt
tgcgagggg aaaactttta acagaagaaa gcacatctcg gccgggctg gtggctcaca
cctgtaatcc caacactttg ggagggcgag gcgggtggat cactagggtca ggagatggag
accatcctgg ctgacacggt gaaacctgt ctctactaaa aacacaaaaa attagccggg
5 cgtgggtggca ggcgcctgta gtcccagcta ctccggaggc tgaggcagga gaatggcctg
aaccggggag gcggaacttg cagtgaagcc aggttgacc actgcactcc agcctgggca
acacagtga actcgtctc aaaaaaaa aaagaaaaga aaagaaatca catctcattc
aagtgggtgc attttaaact atttagcctt tctgtaggca aggttagtat cttgtttttc
cagacctcaa ggtgtttttt tgtttgtttt ttcataccgg tgtgtgtctt ggggtgggcc
10 actaaaagct acaagcaaga aataataaca actacaacaa tactaatacc aatagtataa
aaataatagc atctggctaa ttgctggaca ctgttttaag tggtttgcac gcctcagctc
attaactcat ttacctgtta ttattggccc tattttacaa acaaggagcc aaggctcaga
gcagttaact aacagcctct caaaagaaac tctgcagaga tattaaattt aaaaaataat
gagagaaatt aaaccacaag aaagttgaaa tttagaggta caggcagcta agcttgtttg
15 ctttgaaaca gtgtctgcta ctgggaaaaa ggcaagtctt ggctttccta ataattgata
ccaggactct gtaattcata ttttgcctgc atgtaagtaa gaaatgaagc cgggtgcaat
ggcacatgcc agtaatccca gcactctggg agactgaagt gggaagatca cttgagctca
ggagttcaag accagcctgg gcaactaaaa attaaaaaaa taataatact aattgttttt
atatttagtag attttattca taccacttac atcattattg tagtatgtac atatttattt
20 cttttctttt cttttctttt cttttttgag acggagtctc gctctgtcac ccaggctgga
gtgcaatggc accatatcag ctactgcag catgcgcctc ctgggttcaa gcatttcttc
cacctcagcc tcccaagtag ctgggataac aggcaccac caccatgcct ggctattttt
ttttttcgt agagatggg tccaccatg ttggccaggc tggctctgaa ctccagacct
ccagtgatct gcctgcctcg gcctccaaa ttgctggtat tacaggtgtg agccaccgtg
25 ccagggtggg agatagacat ttctctctac ctcaaacaga ggtccactca agctactttt
cattttcttc ataaatatta gccagtggtc tattttgcac caggaaatggt tccagggtgct
gtggatatgg catcaggcaa aacagaccaa aaacttcctg ccgctgtggc ctcatgttcc
ccaagtggaa gacaggcaat aaagagatag ataaatatgt agtaaattaa aaaaaaaaaa
aattagccgg gtgtgggtgg ttgcacctgt agttccagct acttgggagg ctgaggtggg
30 agaattgctt gagcccaaac gtttgaggct gcggtgaagc atgactgcac tgctgcactc
cagacagcag cctgggtgac aaagcaagac gtttttgtca gaaagaaaaa aaaaagagac
gaaggaggga aggagagaga aaggaaaggaa ggaaggagaa agaaaaggaa gaaggagaaa
gaaaggaagg aaggaaaggag aaagaaaggaa agaaagagaa agaaagaaaa agaaagaaag
aaagaagaaa gaaaagagag aggaagggaag gaaagaaggaa aaagaggga aaaaatgact
35 gttgaagagc agtgagtatt attataggag ggtaattata gggaggtagt gggaaattgaa
gacaggaaac acaaattagt ccaagcgaat ggatttctat tgggagtgat tctgcccta
gaagacactg gcaataccag gagacatttt tggttgtcac aactatatgg aggggcatta
ctggcaacta atggatagat gccagtgtg ctgttcaaca tgctatgatg cacacggcag
gcctccacaa caaaccatta tccagcttca gatgccaca gtgccagat cgaggaacct
40 tcatccaggg gctgagaacc gtatttttgc agaaggagg gagaaataag gcctgcacag gctggagggg
gaatggggaa ggaagggtgt gtgtccagtaa gagaaataag acacgatgag ggagacagc tggaacagaa
agagtgaag agaaaggag gcggagagat acacgatgag gaagggtcac agaccccccc gaaatgatgt
agtagagacg aagattcgag atgtggagag gaagggtgaga gtgacaaatg ggtctaaag
gtggacaaca ggaatctgga agagggaag atggtggctc acgcctgtaa tcccaacact ttggaggctg
45 gttgaacttg gaggccaggc gccaggagtt cgagaccagc ctggccaaca tggtgaaacc
aggtggggcga atcacttgag caaaaaatta gccgggtgtg gtgatggaca cctgtagtca
ccgtctctac aaaaaaata gcaggagaat tgcttgaacc cgggagatgg aggtgcagt
cagctacttg ggaggctgag cgctccaacc tgggcaacag agtaagactc catctcaaaa
50 gagctgaggt caggccactg gtgaaatatt aataacattc tccctctctc tctttttg
aaaaaaaagc tggatttgga tttctgcatt tcttcatctc tgtactttcc atctctgtgt
tgtgtctcca tctctgtctt ccatctatgg gcatctctgg gtctctcatg tctcttctg
gtctgttccc atctgttctt cctctctcat gcccccttt ctctcctgca ggttgattct
cccactttgc cacatctctg cctctctcat cagggactcg tgtctgggg agattacct
ggggggcctg tggctgcaa tggctccctg acgaacctct gcaagttcac caagtggatc
55 tgtgcccgcc ccaacagacc ctcctgagtc atcccaggac tcagaccctc attccttccc agagatgttg
caggaaacca tccaggccaa ctactgagtc atcccaggac tcagaccctc attccttccc agagatgttg
cctgctgcag ggacagccct gacactcctt tcagaccctc attccttccc agagatgttg
agaatgttca tctctccagc ccctgacccc atgtctcctg gactcagggt ctgcttcccc
cacattgggc tgaccgtgtc tctctagtgt aacctggga acaatttcca aaactgtcca

ggggcgggggt tgcgtctcaa tctccctggg gcactttcat cctcaagctc agggcccatc
ccttctctgc agctctgacc caaatttagt cccagaaata aactgagaag

5 SEQ ID NO. 4

hk6 amino acid

10 MKKLMVVLSLIAAAWAEQNKLVHGGPCDKTSHFYQAALYTSGHLLCGGVLIHPLWVLTAAHCKKPNLQVFL
GKHNLRORESSQEQQSSVVRVHPDYDAASHDQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHILGWG
KTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNMLCAGDEKYGKDSQGDGGPLVCGDHLRGLVSWGNI
PC GSKEKPGVYTNVCRYTNWIQKTIQAK

SEQ ID NO. 5

15 KLK6 nucleic acid

CDS 147.. 881

gtcgacccac ggcgtccggct ggctggctcg ctctctctg gggacacaga ggctggcagg
cagcacacag agggacctac gggcagctgt tccttcccc gactcaagaa tccccggagg
cccggaggcc tgcagcagga gcggccatga agaagctgat ggtggtgctg agtctgattg
20 ctgcagcctg ggcagaggag cagaataagt tgggtcatgg cggaccctgc gacaagacat
ctcaccctta ccaagctgcc ctctacacct cgggccactt gctctgtggt ggggtcctta
tccatccact gtgggtcttc acagctgcc actgcaaaaa accgaatctt cagggtcttc
tggggaagca taaccttcgg caaagggaga gttcccagga gcagagttct gttgtccggg
ctgtgatcca ccctgactat gatgccgcca gccatgacca ggacatcatg ctgttgccgc
25 tggcacgccc agccaaactc tctgaactca tccagcccct tccccggag agggactgct
cagccaacac caccagctgc cacatcttgg gctggggcaa gacagcagat ggtgatttcc
ctgacaccaa ccagtgtgca tacatccacc tgggtgtccc tgaggagtgt gacatgcct
accttgcca gatcaccag aacatgttgt gtgctgggga tgagaagtac gggaggattt
cctgccaggg tgattctggg ggtccgctgg tatgtggaga ccacctccga ggccttgtgt
30 catggggtaa catcccctgt ggatcaaaag agaagccagg agtctacacc aacgtctgca
gatacacgaa ctggatccaa aaaaccattc aggccaaagt accctgacat gtgacatcta
cctcccagac taccaccca ctggctgggt ccagaacgtc tctcacctag accttgccct
ccctctctc ctgcccagct ctgacctga tgcttaataa acgcagcgac gtgagggtcc
tgattctccc tgggtttacc ccagctccat ccttgcatca ctggggagga cgtgatgagt
35 gaggacttgg gtcctcggtc ttacccccac cactaagaga atacaggaaaatcccttcta
ggcatctctc ctcccaacc cttccacacg tttgatttct tcctgcagaggccagccac
gtgtctggaa tcccagctcc gctgcttact gtcggtgtcc ccttgggatgtaccttctt
cactgcagat ttctcacctg taagatgaag ataaggatga tacagtctccataaggcagt
ggctgttggg aagatttaag gtttcacacc tatgacatac atggaatagcacctgggcca
40 ccatgcactc aataaagaat gaattttatt atgaaaaaaa aaaaaaaaaa aaaaaaaaaa
agggcgccg c

SEQ ID NO. 6

KLK6 nucleic acid

45 mRNA join(2001..2185,3084..3135,3559..3606,4346..4502,
8122..8369,9791..9927,11805..12483)

CDS join (3567..3606,4346..4502,8122..8369,9791..9927, 11805..11957)

50 acacttaaaa aatcttctga cttaaaaaaa aaagtatggt gattggaaaa tgtaaatgtg
catgcgtgct tggcatcaca ttcatattgc caggacttcc ctggatgcta aaggctctca
aatgccaggc tggggggctg ggacttggtc ccaagggaga tggggaccca gggcacgtct
gtgagaggag gggcaaggtc agcacaaggc acaggaaggc ctctctgggg caagggatac
agagaacaga gggatcctgg tccagggtgg agaggtgcag ctctgagttg ggggtgaggg
55 tgtgggtaca gagaggaagg gacccccag agagaggagg cagagggata gggcctggct
actgggttgt gcaacatcag acttgctgtc tgtgaagata gcacgtcctg agaagaagg

	gctgaggtca	gtggggacca	aatgtgagag	ggagcaccgg	gagagtatac	tgaataccga
	agtagtcttc	atccctggag	tgatgggggg	tgacacaatgc	aagatgacaa	ttagattcaa
	tgcaagacaa	agaaaagggg	tggtctgggaa	cagtgggtca	tgccataggt	cccagctcct
	gggaagactg	aggcgggagg	gtcgcttgag	cccaggaggg	ttgaggctgc	cacgagcaag
5	gatcgtgcc	ctgcaactcca	gcctaggcga	cagaacaaga	ccttgtctca	aaagaaaaaa
	gaactttttt	ttttaagtta	cctgtagtgc	ccagcccaag	caggtgtgta	gccagacttc
	atcctatca	ttgtccttat	tacgcagtga	cttccccctc	ctcattttctc	tccactctgc
	cacgcacaca	ccctcacccct	ccagcccata	ccaaccaccc	caaccactgc	ctgtgggttc
	ccatgtgcac	ccaggccagg	catttttcacg	gcctttctctc	ctgacctaag	cctggctcag
10	ctttctaggc	ccaagttaaa	agacacctcc	ctaaatcttc	ccagatccct	ctgctactgc
	ccagcaccac	catcttatca	cagccccacg	tcgttcccaa	gtgctctccg	atttctgctt
	aatccatgc	ctctcgctgt	gtgtccgcat	ctcatcaata	agtccctcaag	tccctctcca
	tccctgctagc	ttcctcatcg	ctcggaatc	atccccgcta	cttccctggg	aaactgactc
	ccttctgggc	acacacagt	ctacccccgg	ggaaatctaa	gaagagaccc	aggagaagat
15	aagcacggag	agtcagagaa	tcaaggggaa	agaaagggag	agaggccggg	cacagtggct
	cacacctgta	atccagcact	ttgggaggcc	aagggtgggtg	gatcacctga	ggtcaggagt
	ttgagaccag	cctggccaac	atggtgaaac	ctcttcccta	ctaaaaatac	aaaaaacatt
	tagccgggcg	tggtgtgtgg	tgctgtaat	cccagctact	tggaagctg	aggcaggaga
	actgcttgaa	ctcaggaggc	ggaggttgca	gtgaactgag	atcacaccac	tgactccag
20	cctgagtgac	agagcaagac	tccgtcaaaa	aaaaagaaag	aaagaaagaa	aagaaggaag
	gaaagaaaga	aggaaggaag	gaagggagga	aggagagagag	gaagggagag	aggaagggag
	agagagaaaa	aaagagggag	agagacacaa	atacagagac	tgagatggga	gagagagaga
	gatggaagct	ccctcccctc	catggccagg	gagacagatg	gagcaagaga	cctcagggtg
	gggcagactt	ggaggagaag	gaccaggagg	atgtggagt	ccgaaatctc	cagtcaaggc
25	caggtgggca	gtcagagact	gcaaaggagg	actgtcagac	agggacaaaa	ggaagccatt
	gatgtaaccg	ccctcccggc	tgcccggcgg	aagagagggt	gaggccggag	ctgctgggag
	catggcactg	gggtgctggg	aggcggacaa	agcccagattg	ttcctgggco	ctttcccat
	cgcgcctggg	cctgctccc	agcccggggc	agggcggggg	gccagtgtgg	tgacacacgc
	tgtagctgtc	tccccggctg	gctggctcgc	tctctcctgg	ggacacagag	gtcggcaggc
30	agcacacaga	gggacctacg	ggcagggtgtg	tgagtacccc	caaccgcact	gaacctgggc
	aggctgcttc	ccagtgcggg	agggtcttag	agcccggagt	gagggcctgc	aggctccctg
	gtggcacaga	gagtgtctgg	ggtgcaggga	ggcctggggc	accatctgct	tgccccagag
	gccggaattt	gtcttcagac	actttcttct	tccaaaaccc	ggaggtctaa	ggactgagcc
	gactagaact	tcctctgcct	cagattcagg	cccagcccc	tcctccctca	gaccaggag
35	tttaggtcct	agcccctcct	ccctcagacc	caggagtcca	agttcccacc	tcctccctca
	gactcaggag	tccaggcccc	cagcccctcc	tccctcagac	ccaggagtcc	aagtctctac
	ctcctcccctc	agaccagga	gtccaggccc	caagcccctc	ctcccctcaga	cgaagggtc
	caggccccca	gcccctcctc	cctcagactc	aggagtccag	gcccccaagc	ccctcctccc
	tcagacccag	gagtccaggc	cctcactgca	ctcagggacc	agtgtctcct	tccttgagg
40	cctggtcagg	ggtcaccaag	agcagagcgt	ggggggcgga	ggaatgtgtg	tgggaggcct
	gggtaaggag	gaaaagggtg	tagccagtct	cctgggtcag	ggacctgaga	gacaggggtt
	aaaaggacgt	tccagaagca	tctggggaca	gaaccagcct	cttccaggga	ggcctgggag
	ctgggggtgt	gtgtctggca	gtccctgcag	ccctgggtctc	tgccggccct	gcgtcctccg
	cttggtcttg	ccactgcac	tgagtgtctt	ctctcctcac	ggctccccgc	atttctaact
45	ctttctgcct	cctcgtctca	aagctgttcc	ttccccgcac	tcaagaatcc	ccggaggccc
	ggaggcctgc	agcagggtgag	atcacagaca	tcacagaacc	tgccgggtgg	gcgggggtgg
	tgcccatgtc	gcacagagcc	aggctccgag	gaaaactccc	atacagagga	agaacgctag
	ggccccctat	ggttaaccctc	tcctgtcgac	aggaaggcaa	atcagtgcct	aagaaagtag
	aaagatctaa	tcagaatctc	accatgggtt	actggaccag	tggaagtagt	tgaattctct
50	ttggcactgt	tttcgtggat	cctcttgga	gatgtgggct	gaggaagaat	aaatcaggag
	gctagatggg	aaggacagag	gtcaaggcag	gagaccatag	caggccagga	aggaaggaga
	ggatgcagag	ggagcagaca	gagggatggg	gggagggtcg	aggcagtgc	taatggacca
	tgtggcttcc	cctctcagga	gcggccatga	agaagctgat	ggtgtgtctg	agtctgattg
	ctgcagggtg	ggaaagggca	tttggatggg	ggaggcttgc	agacaggggt	gggcttgttg
55	atggagaaga	ggctgggtatt	ggggatgggg	atatgcacag	gggtgggggtg	ggggagcttt
	gaaatgagga	agacgttggg	gattaggcta	aggggtggga	atacagatag	ggagggtggg
	gggaggtggg	tttgaagata	tgagggtttg	gggtgggggt	ggctttaggg	atggggatct
	aaacatagaa	gaggtaggag	gtaggttggg	aagttggaga	gagccccgga	ataggggata
	cagttggggt	tgtaattggga	atgggtaag	tttgggagtg	gaaatacaga	gaagcttttt

	ttttttgaga	caggggtotca	ctctgtcacc	caggtctggag	tgtagtggca	tgatccatag
	ttcactgcag	acttgaactc	ttgggtctca	agtgaacctc	ccacctcagc	ctcccaagta
	gctgggacta	cagggcgtatg	ccaccatacc	ctgctaattt	gtgtgtgtgt	gtgtgtgtgt
	gtgtgtgtgt	gtgtgtgtgg	agatgaggtc	tcactgtgtt	accgaggctg	gtctcaaact
5	cctgggctca	agcgatcctc	ctgcctcagc	tgggattaca	ggcataagcc	actgcacctg
	accaatcttg	actggagttc	atgttgaggg	ggatgcgctt	ggtttctcca	gaactcctct
	ctgactcaga	tcttctctcc	ctcagcctgg	gcagaggagc	agaataagtt	gggtgatggc
	ggacctgcg	acaagacatc	tcacctctac	caagctgccc	tctacacctc	gggcaccttg
	ctctgtgggtg	gggtccttat	ccatccactg	tgggtcctca	cagctgcccc	ctgcaaaaaa
10	ccgtgagttc	acactgtaaa	tgaacagcag	atgcgactga	accctgaggg	tgtcttatag
	atgtcaggca	ggaggtgaca	taggcacccc	ccccatcccc	gcacgaggcc	atctgatagc
	caggtgcatt	cggctgttgc	ttaattgagt	acttaatgtg	tgccaggccc	tgcgggcata
	gcagtggaaa	agaaaaataa	aaaaagaaaa	caaaaaaaa	caagcaaaat	tgctgttttc
	ctgaacttac	tttctaattg	gggaattgga	tcatttgagg	acctgcaggg	cgtgatgggc
15	atttggtatt	aattctgagc	acagtaggaa	gccactgggc	agttttgttt	ttgtgttttg
	tttggttttt	gagacacagt	ctcgctctgt	caccaggctt	ggagtgtagt	ggcatgatct
	cagctcactg	caacctctgc	ctcccaggtt	ccagcgattc	tcctgcctca	gcaccccaag
	tagctgagat	tacagtggtg	caccaccttg	cctggctaata	ttttgtatgt	ttggtagaga
	cgggggtttca	ccatgttggc	caggctggtc	tcgaactcct	gacctcaggt	gatccgcccg
20	cctcgccctc	ccaaagagct	gggattacag	gcatgagcca	ccaccacacc	cagcctgatt
	tacattttta	caagcaccct	ggctaccacg	tggaacgtgg	tctgggcaag	agagagggag
	ggaggcccac	gtgggggctg	ttgctttcat	ccggcgacat	aggaggggtg	cttgaaccca
	ggcggctcgca	gtggggatgg	agggatgttg	aatatcttgg	gatgtggaat	tctgagactg
	agccagcaga	atctggcaac	gaggaacagg	agggagagga	agaagcacgg	ctggcttccg
25	tgtattttgtc	ctgaacaact	gggtgttttg	ccacgtcttt	ctctgagttg	tgggagaggg
	aaagagaaaac	aggccgggtg	taggcagggg	agcatctgac	attttgcttt	agccacgatg
	agttggagat	gccggggaga	tgtcccagca	gggaggccag	ggaggactct	ggagctcaga
	ggagagggtca	gggctggagg	ttaaaatgaa	ggcatcgtca	gcaaacaggt	gtatttaaa
	ccatgggact	agatgagatc	atccaaaaag	ctggcatagt	tggaggagct	ggagggccca
30	ggacaaaaac	cctgggcgct	gatcctcact	agtcagattc	acgacagctg	ccacttgttt
	gatgctaact	accaatcagg	tgctgagtga	aaccatgtac	acacctttcc	tggaatgcc
	accacaaggg	actcttggca	ccattttgca	aatgaggaaa	ctgaggtgca	gggaaatagc
	aagtgcacat	ccctgggggtg	gttcccctga	ccccaggag	accttggtatg	actctcacca
	ccatcattca	ttcctttgat	gtacattgac	taagagcacc	tgctaagtgc	cacattcgag
35	ttgggcagtg	gagattcagc	aatggatggg	acacacacgt	catccctgcc	ctcgggagca
	caaggacaga	aaggtgcaga	caagcaaagt	gagggctggg	catggtggct	cacgcctgta
	atcccagcac	tttgggaggc	cgaggtgggt	ggattacctg	agttcgagac	cagcttggcc
	aacatggctc	aacctgtctc	ctactgaaaa	tacaaaaaat	tagccaggcg	tgggtggtggg
	cttctgtaat	tcagcaact	tgggaggcta	aggcaggaga	attgcttgaa	cgtgggaggc
40	ggaggttgca	gtgagccgag	atcgccgac	tgcaactccag	cctgaaccac	agagcgagac
	tctgtctaaa	aaaaaaaaaa	ggaaagaaag	aagcagcaaa	ttgggctggc	cgtggtggct
	catgcctgta	atcccagcac	tttgggaggc	cgaggcgggt	ggatcactcg	agcccaggag
	tacaaagctg	cagtgaactg	tgtctacag	aacaccactg	cagatccagc	ctgggtgaca
	gagcgagacc	ctgtctcaaa	aaaacaaaac	aacaaaagaa	gcaaaccctt	caaaacccca
45	tataattaca	aattatgaag	gaaaagaata	cgggtacctc	ctttagatgg	aggaggggtca
	ggaaggactt	tctaattgaga	taaaatccaa	gaggaggcat	gaagatggga	aaaggaatgt
	tcagggcaga	ggaaaggctg	tgataacacc	cctgaggtga	gaaccgtctt	gagtatcttc
	agaaaaataa	atttcccgtt	cactgggggg	cagaaggtgc	tgggagataa	ggttggaag
	tgactacagc	cagatcacac	aggggctcca	gtgccaagtg	gaggagccca	ggctttattc
50	ttaggacaat	ggggagccat	gggtgatgtc	tgagcaaggg	agtgactctc	tgtttcagga
	atatgtatca	aacacctatc	ctgtgccagg	tgctgatcaa	cgactggag	atactatata
	tgaatagaac	aaaaatcccc	atcttgacat	cctagagctg	cactgtctaa	tatggtagcc
	atcagccaca	tatagcaaat	tacattgaaa	ttaatgaaat	ggaaaatcca	caagccacat
	ttcaagtact	cagcagccac	ctgtagcttg	tggttccccc	agccacctct	ggacagtgca
55	gtcagagatc	atggcatcgt	agcatttagt	ggacagcatt	gctctgcaag	gaggagaaat
	aacacaatga	gtaaatattt	aacaataaat	atatagcagg	tcggatgatt	gtgatagggt
	ctctggtgga	acagaaagca	ggggaggggg	ataggaattg	cctactaaca	ggtatttgta
	ttttaattgg	gcaactaagg	aaggcttccc	tgagaggcga	catttaaagg	aagtgaagga
	gtgagctatg	cagatacttg	gaggacagac	ttgctggcag	agggaacagc	agtgaagga

ccctgaggtg ggaagatcac tattgtgttc aaggcaagac agggaagcca gcgtttggct
 ggagcagagg gagagaagg gagagtggga ggagaagatg tctgtgagat gatggggcag
 tgcttgcaag gcctgggtgtg ccacgttgag aactttggct ttgattctga gtgagatggg
 agtcatagga ggggctgagc agaggaggca caggaccaac ttacattgtt aaaatatctc
 5 tggttgcttt gtggaggatg gactgtgggg gaccagagac agagcaggga gccagtgag
 gaggtactg ctctagtcca ggttaggaagt gaaaaggcag ctcaaaccaa gatggtagcc
 gtgggaaaag tgagatgtgg ccagattctg gatatgcttc agagaggcaa aaggaattct
 ggacagcttg gatgtagggc atgaaataaa gagagtgaag aatagccccc aagattattc
 tgaaaggatg gaattgccat ttaccagct ggggaagact gtgggaggag caggccagcg
 10 attcatgact tcccagccct ctctgaagcc tcaactgcag cccaagggct ccaggtgaga
 cccagccctc ttccttccca ggaatcttca ggtcttctct gggaagcata accttcggca
 aagggagagt tcccaggagc agagtctctg tgtccgggct gtgatccacc ctgactatga
 tgccgccagc catgaccagg acatcatgct gttgcgcctg gcacgccag ccaactctc
 tgaactcatc cagccccctc ccctggagag ggactgctca gccaacacca ccagctgcca
 15 catcctgggc tggggcaaga cagcagatgg tcagtagtgg gaggtctgtg gggagcaggc
 tactggctac ttggggaagt gtgccaaagg atggggagtg ggaaaattgg tgaggggcca
 tgggaagatg ggctaattgt gaggaccaat gggacagggt ttcaatggga gaaaggtcaa
 gggggaggga gagtgaattt gggagctggg ccagttagtg aacagccaat ggaaaatgta
 gaccaatggg tgaatagcat gggagagatg gaacataaga tgaagggtca ataaagaggg
 20 aaggtcagtg gggagatgct aatcaggaa gtagtcaaag gtcaaagggg actgatcagg
 attcattgaa cagcaggaag gaataatgga gaaggaaact atggaagaag agaaccaat
 aaagcacaaa agccaactga aggatgtgaa ttgagacagt gaatgggggt atagctgatg
 gaagagggac taaggggaaa ggatcaatgg tccagaggag tccactagagg tcaaaaacagg
 tccaatagat cagcaggatc catgaagggt ggctgtgtg tgaagggccca ataaagagg
 25 tgaaccattg gatgaagggc cagtgggaag gcagagacaa tgggggagga tgcggcaagt
 tagaaaagga ccaatgaggg aggtggacca ttgatgaag ggctaataag aagggagagc
 cagtggggga tggtagggcc agttagaaaa ggaccaagga gggaagcaga ccaataggaa
 gagagagcca atgagggagg gcagggccag ttaggaaagg accaatgagg aaggtagacc
 attggaggaa gggccaatag aaagggagga tccatgagg aggggtggga cagttagaaa
 30 aggaccaatg atggaggtgg accattggat gaagaaccaa tagaaaggaa gaaccaatgg
 gagagggcat ggccagttag gaaaagacca atggtcacag agtgaccaat caagatgaat
 caatgggcag gaagtgtcca atgaagaatg gactactgat caggaggggt acagtagagg
 agggcgtaac agaggaagag tctccaggt caactgaaac tactgaagaa ggtgggacca
 35 gtggaagaga gaaaagtggg ggagggacct aagagaaaa gaaaaccaat aggaaatgag
 gactcctgga gaagagacta ttaatgagga agacagccaa tgggggggaa gaatgataga
 aagagggacc aattaggagg cagggacgat ggtaatgaga tgtaagaatg agagacaaac
 aggaagagggt gtgccaatag aaaagaggga ccaatagagg atggaggact tataggggtt
 ggggggtgac tggggaggat gaggggagt caaggcctgg gctgagtctg gcccatctct
 40 cccctaacag gtgatttccc tgacaccatc cagtgtgcac acatccacct ggtgtccctg
 gaggagtgtg agcatgccta ccctggccag atcaccaga acatgtttgt tgctggggat
 gagaagtacg ggaaggattc ctgccaggtg aggtgacctg gatctgccac ttacacagcc
 agggacagga cgaagtcaca aaaacatggc cagacacagg aagagagaga cacaggccaa
 aagagagctt tacagagaca gatagagaca ggctgaggga gaaccaagc cttgaaaaga
 45 agagacttag ttcaacacac agagacacag tcaggatatat gcagagatat aaagacacag
 ccagcagaga cagggaagtgc agagacaagg atggaggccg cgggatcaag aaccagagag
 gccaggagca gcggctcatg cctgtaatcc cggcactttg ggaggccgaa gcaggaggat
 cacctaggggt caggagtctg agaccagcct gatcaacatg gtgaaaccct atctctacta
 aaaatacaaa aattaggatg ggcacagtgg ctcatgcctg taatcccagc accttgggag
 gccgaagcag gaggatcacc tggggtcagg agttcgagac cagcctgatc aacatggtga
 50 aaccctatct ctactaaaaa tacaaaaatt aggatgggca cagtggctca tgctgtaat
 cccagcacct tgggaggccg aagcaggagg atcacctggg gtcaagagat tgagaccagc
 ctggccgata tggtgaaacc ctatctctac taaaaataca aaaattagct gggcctggtg
 caggcgctgt tagtcccagc tactcaggag gctgtggcag gagaatcact tgaacctgga
 55 ggcggaggtt gttgcagtga gtcgagatca tgctactgca ctccagcctg gcaacagagc
 aagattccgt ctcaaaaaaa aacaaaaatt cgaagcatgg tgggacacac aggagggcaga
 ctgtagtccc agctactcgg gaggctgagg ctggagaatt gcttaaaacc ccagactctg
 ggctgcagtg agctgagatc acgccactgc actccagcct ggggacagag aggggactgt
 tctaaaaaca aaaagaacca aagagaagta gtaaggaagc agatggtgtg aggggactgt

```

ccttctctcaa acagagcccc cacgagtcct gctcagaaac gaccaggctc tggaggaggag
agacactagc tggggaaagg ggactccctc ccgaatactt taacttgggt ttcctccatt
gtcatccatc caggctctcc tctttatgcc agaataacta atgcactgag ggatgtgcag
agaccaacca aggggggagac acaggcagaa acggagacac aggcagaaac agggacagag
5 acagggaaaag cgatacatag caagttggac gcaaagaaaag ggcaggtggg cgagactgtc
ctcaagacac gaggtggaga ggtgtccctg gacagaatag tgccaggcat atctctccct
gggcccctccc tacctctccc acctgggtct tatcgtctcc tctccccct cctccctctc
ctcctcttcc tctcctctcc cctccctcat catcttcttc tttctctct ctctccatcg
gtctctacac ctctgcctct ctccacacct ctacgtctcc attcttaaat tgtttctctt
10 tcttgctctc tatgttctct tgcatcttgg cattcctatc tctgtgtctt tgagtctctc
ttattctctc tctaccatct tctctctgtg cctttgtgtg tcttactgtc tctctctctg
tctctctgtc cctgagtcct tctctccatc tttcagtaag tacctctgtc cctttctacc
tctctctctg tcacacacac acacacacac acacacacac acacacagtc acacacagtc
tctgggtttc tatctgtatc tgactttctc cctctttcct gcagggtgat tctgggggtc
15 cgctggtatg tggagaccac ctccgaggcc ttgtgtcatg gggtaacatc cctgtggat
caaaggagaa gccaggagtc tacaccaacg tctgcagata cacgaactgg atccaaaaaa
ccattcaggc caagtgaccc tgacatgtga catctacctc ccgacctacc accccactgg
ctggttccag aacgtctctc acctagacct tgccctccct cctctcctgc ccagctctga
cctgatgtct taataaacgc agcgacgtga gggctcctgat tctccctggt tttaccccag
20 ctccatctct gcatcactgg ggaggacgtg atgagtgagg acttgggtcc tgggtcttac
ccccaccact aagagaatac aggaaaatcc cttctaggca tctcctctcc ccaacctctc
cacacgtttg atttcttctc gcagaggccc agccacgtgt ctggaatccc agctccgctg
cttactgtcg gtgtcccctt gggatgtacc tttcttctac gcagatttct cacctgtaag
atgaagataa ggatgataca gtctccataa ggcagtggtt gttggaaaga ttttaagggtt
25 cacacctatg acatacatgg aatagcacct gggccaccat gcaactcaata aagaatgaat
ttt

```

30 SEQ ID NO. 7

KLK6 nucleic acid

CDS 246..980

```

35 agggcgacaa agcccgattg ttcctgggcc ctttcccat cgcgccctggg cctgtctccc
agcccggggc aggggcgggg gccagtgtgg tgacacacgc tgtagctgtc tcccggctg
gttggtctgc tctctcctgg ggacacagag gtcggcaggc agcacacaga gggacctacg
ggcagctgtt ccttcccccg actcaagaat ccccgagggc ccggaggcct gcagcaggag
40 cggccatgaa gaagctgatg gtggtgctga gtctgattgc tgcagcctgg gcagaggagc
agaataagtt ggtgcatggc ggaccctgcg acaagacatc tcacccctac caagctgccc
tctacacctc gggccacttg ctctgtggtg gggctcctat ccatccactg tgggtcctca
cagctgcccc ctgcaaaaaa ccgaatcttc aggtcttctt ggggaagcat aaccttcggc
aaagggagag ttcccaggag cagagttctg ttgtccgggc tgtgatccac cctgactatg
45 atgccgccag ccatgaccag gacatcatgc tgttgcgcct ggcacgcca gccaaactct
ctgaactcat ccagcccctt cccttgagga gggactgtct agccaacacc accagctgcc
acatcctggg ctggggcaag acagcagatg gtgatttccc tgacaccatc cagtgtgcat
acatccacct ggtgtccgtg gaggagtgtg agcatgccta cctggccag atcacccaga
50 acatgttgtg tgctggggat gagaagtacg ggaaggattc ctgccagggt gattctgggg
gtccgctggg atgtggagac cacctccgag gccttgtgtc atggggtaac atcccctgtg
gatcaaagga gaagccagga gtctacacca acgtctgcag atacacgaac tggatccaaa
aaaccattca ggccaagtga ccctgacatg tgacatctac ctcccagct accaccccac
55 tggctggttc cagaacgtct ctcacctaga ccttgcctcc cctcctctcc tggccagctc
tgacctgat gcttaataaa ccagcgcagc tgagggtcct gattctccct ggttttacc
cagctccatc cttgcatcac tggggaggac gtgatgagtg aggacttggg tctcgtgtct
tacccccacc actaagagaa tacaggaaaa tcccttctag gcatctctc tcccaaccc
60 ttccacacgt ttgatttctt cctgcagagg cccagccacg tgtctggaat cccagctccg
ctgcttactg tcggtgtccc cttgggatgt acctttcttc actgcagatt tctcacctgt

```

10/16

aagatgaaga taaggatgat acagtctcca tcaggcagtg gctggttgaa agatttaaga
tttcacacct atgacatata tgggatagca cctgggcccgc catgcactca ataaagaatg
tatttt

5

SEQ ID NO. 8

Hk10 amino acid

MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRL

10 PEAYGAPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDHLL
LLQGEQLRRRTTRSVVHPKYHQSGPILPRRTDEHDLMLLKLARPVVPGPRVRALQLPY
RCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVTTNNMICAGL
DRGQDPCQSDSGGPLVCDLTLQILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN

15

SEQ ID NO. 9

KLK10 nucleic acid

Gene 1...1580

CDS 220...1050

20

catcctgccca cccctagcct tgctggggac gtgaaccctc tccccgcgcc tgggaagcct
tcttggcacc gggaccggga gaatccccac ggaagccagt tccaaaaggg atgaaaaggg
ggcgtttcgg gcactgggag aagcctgtat tccagggccc ctcccagagc aggaatctgg
25 gaccagaggag tgccagcctc acccacgcag atcctggcca tgagagctcc gcacctccac
ctctccgccc cctctggcgc ccgggctctg gcgaagctgc tgccgctgct gatggcgcaa
ctctgggccc cagaggcggc gctgctcccc caaaacgaca cgcgcttgga cccgaagcc
tatggctccc cgtgcgcgcg cggtctgcag ccctggcagg tctcgctctt caacggcctc
tcgttccact gcgcgggtgt cctggtggac cagagttggg tgctgacggc cgcgactgc
30 ggaaacaagc cactgtgggc tcgagtaggg gatgaccacc tgctgcttct tcagggagag
cagctccgcc ggaccactcg ctctgttgtc catcccaagt accaccaggg ctcaggcccc
atcctgccaa ggcgaaacgga tgagcacgat ctcatgttgc tgaagctggc caggcccgtg
gtgctggggc ccgcgctccg ggccctgcag cttccctacc gctgtgctca gcccgagac
cagtgcagg ttgctggtg gggcaccacg gccgcccga gagtgaagta caacaagggc
35 ctgacctgct ccagcatcac tatcctgagc cctaaagagt gtgaggtctt ctaccctggc
gtggtcacca acaacatgat atgtgctgga ctggaccggg gccaggacct ttgccagagt
gactctggag gcccctggt ctgtgacgag accctccaag gcatcctctc gtgggtgtgt
taccctgtg gctctgcccc gcatccagct gtctacaccc agatctgcaa atacatgtcc
tggatcaata aagtcatacg ctccaactga tccagatgct acgctccagc tgatccagat
40 gttatgctcc tgctgatcca gatgccaga ggctccatcg tccatcctct tccctcccag
tcggctgaac tctcccttg tctgactgt tcaaacctct gccgcccctc acacctctaa
acatctcccc tctcacctca tccccccacc tatccccatt ctctgectgt actgaagctg
aatgcagga agtggtggca aaggtttatt ccagagaagc caggaagccg gtcacaccc
agcctctgag agcagttact ggggtcacc aacctgactt cctctgccac tccctgctgt
45 gtgactttgg gcaagccaag tgcctctct gaacctcagt ttcctcatct gcaaaatggg
aacaatgacg tgcctacctc ttagacatgt tgtgaggaga ctatgatata acatgtgtat
gtaaatcttc atggtgattg tcatgtaagg cttaacacag tgggtggtga gttctgacta
aaggttacct gttgtcgtga

50

SEQ ID NO. 10

KLK10 nucleic acid

Gene 1..5574

mRNA join(48..120,605..701,2455..2635,3589..3863,4195..4328, 4793..5474)

55

CDS join(614..701,2455..2635,3589..3863,4195..4328,4793..4945)

Promoter 1...47
 5'UTR join(48...120,605...613)
 exon 48...120
 exon 605...701

```

5      ttgggggtcaa aagggaaggt cccgccaggg gtccctgggc agaggatacc agcggcagac
      cacaggcagg gcagaggcac gtctgggtcc cctccctcct tcctatcggc gactcccagg
      tgaagctacc tgcaccccac ccgggttggg gtggattgag agaggatggg tgggaacccc
      cgggccacag gcaggagccg gcttagagcc tcggtttctc cactgcgagg cgcggaagtc
10     cccccgctgt gaggttgaga aagaggctcc cactggctcc gagcctcgga tccccacccc
      gcgcgtgaag gagggggaaa cctcggggcg ggcgtggctg cagccagggt agctggggcg
      cggagagcgc tccactcggg cacagggagg acgggaagat gccgcgaggg gcgtcattag
      ggtaattgtg cccattaccg tgttcagacc cgaatctccc gtctgccagc ccttgggggtt
      atcggctgca ggtcaaaagg gtgcttgccg gctgggggtg gccaggctgg gcggtgagc
15     gcggcgagggt ggggggtctct aacggagcat ctgttttaac ccgccctcgc acacacccca
      gcagatcctg gccatgagag ctccgcacct ccacctctcc gccgcctctg gcgcccgggc
      tctggcggaag ctgctgccgc tgcgtatggc gcaactctgg ggtaagggtg gggacagggg
      gcggggagag gcgcgggtgg gaggcacggg cgggagggca atgtgttccc gtcaccaagg
      ccgcgcgacc tctcctcccc cgagacccca gcaccacccc agcgtcccg agcacggccc
20     gcccccaagt cagctgggcc ctctctctgg ctccggccct gggtgaccgc cccactcag
      gccctgtccg atttctgcca cccgatcctc cgctcttccg tggactcttc ggcgtgttct
      ttctcctcct cttacgcgcg cccatcccgg ccccgctcca ttttactacta ccgtgttttg
      ttttgtttgt ttgtttgttt gagacggagt ctgctctgt ctcccgggtt cacaccattc tctgcctca
      ggcgcatctc cggtcactg caagctccgc ctcccgggtt caccaccattc tctgcctca
25     gcctcccgag tagctgggac tacaggcgcc cgccaccaag cccggctagt ttttgtatt
      tttagtagag atgggatttc accgtggtct cgatctcctg gcctcgtgat ccgctgcct
      cggcctccca aagtgtctggg attacaagcg tgagccaccg ctcccggcca caccacagt
      ttttatcctg agtcttgcc taccgctttt tgccctctcc cctcactttt tttcttctc
      ttcccttttc tctctctttt ttctttttct ttctttcttt tctttctttc gttcttcttt
30     tccttccttc ctttctcttc ttctttctgt ttgtttcttc tttcttcttc tactttctct
      cttatttttt cttctttctt tctgtttttt tttctttctc tctcttttct tttcttctt
      tttttttttt tttttttgag acagggcagt gctctgtctc cgtggctgga gtacagtggc
      ccaatcagag ctactgcag cctcgacctc ctgggctcaa gcgatactca gcctccagag
      tagctggtag cacaggcatg caccaccaca tccggctttt tttttttttt gttttttttt
35     tttttttgag acagggtctc actctgtcgc ccagactgga gtgcagtggc ccaatctcgg
      ctcatgcaa cctccacctc ctgggctcaa gcgatcctcc caccctcagcc tcccaggtag
      ctgtgactac aggcgcagtc ctccgcgact acttttttgt tgttggttgt gttgttttgt
      tttgttagag actgggtctt gctgtgttgc ccgggctggg cttgaattcc cgagctcaag
      cgttccaacc gcctcggtt cccaaagtgc tgggattaca ggcgtaaac actgcgcccc
40     accctctccc tgggtttcaa tccggttttg ttattcacac cccttctct ccccgatccc
      cgagttctat ccccgcaccc ttacctcccc gccgcgttca atccccgccc ctctatcgac
      cagcgacgtt ctagccagct ctccaggcgc gctgcgttca gtccctgccc tccagaccca
      ccctattctg tctcattact ccacgctacc ctatcccagc ttcttccac tttcacgcgc
      ttcttctcct cccattcctt cgggtgcacgc gaaaccccc atatttccct accaccctcg
45     cgttctggct gcgtccccc tccccgaacg cagtccagtg ccacagcca gttccaacce
      caaacccaga ccctgccctc cgtgttttga ttccgtcccc tttctttctc ccagccgcag
      aggcggcgct gctcccccaa aacgacacgc gcttggaccc cgaagcctat ggcgccccgt
      gcgcgcgcgg ctgcagccc tggcaggtct cgctcttcaa cggcctctcg ttccactgag
      cgggtgtcct ggtggaccag agttgggtgc tgacggccgc gcaactgcga aacaagttag
50     aggagatcca tccccagga cgccacgggg ggctgtggag gcggcctcca gggaggagcg
      ggcaggggcg ggtctctcgg aactcccaca gctggagggt cgggtccccg tgtccttcca
      gcaggaggag agaccgggct tgcgtgtggt ccgccagggg acggtgtggt ccttttccgc
      atttctgggc ccgtcactcc tctcccgtg attctccttg agctctagga ggaggtgggt
      gcctgcaacg gatagaagcc agggctccgt gtggtcagga atttagaact aaaggaaaag
55     gttcacttcg tgagtcctcg ttgaaggagg aagggttggg tattaccaca gagaaaatgt
      ggagttgggc tgggctcggg ggctcacggt tgtaatccca gcaacttggg aggccaaggc
      ggggtgatca cctgaggtca ggagttcaag accagcctgg ccaacatggt gaaaccactt
      ctcaactaaa aataaaataa aataaaaaat aaaaaatttt aaaaaaatta aaaaaaaaaa
      aaggctgggt gtggtggcgg gtgcctgtaa tcccagctac tcaggaagga ggctgaggca

```


ggagaactgc ttgaacctgg gaggtggagg ttgcagttag cccagattgc gccattgcat
 tctagcctgg gtgacaagag cgaaactctg tttcaacaaa gaaaagaaaa agagaaaaga
 aaatgtggaa ggcttaccta ggtgtccagg cccccagccc tccccaattc ctgcagatcc
 tcagagctca aacaactgat tccctctccc catgtccact gaggtcccct tctcccacaa
 5 ggccctcttc cctcagactc ttctatcttc caggccctgc ttactgccc acctgctttc
 ccagtccttg tgaagggttt gccttcacat gcctcttcct tccccaggg cactgtgggg
 tcgagtaggg gatgaccacc tgctgtctct tcaggggcag cagctccgcc ggacgactcg
 ctctgtttgt catcccaagt accaccaggg ctcaggcccc atoctgcaa ggcgaacgga
 tgagcacgat ctcatgttgc taaagctggc caggcccgtg gtgcccgggg cccgcgtccg
 10 ggccctgcag cttccctacc gctgtgctca gcccggagac cagtgccagg ttgctggctg
 gggcaccacg gccgcccgga gaggcaagag ctggggctct gaggccagaa cctcaggagg
 agggggctga gggcctgaac ccctgggtct gaggaaggat gggctgggga ctggattcct
 ggatctgagg gaggacgggc tggggctcta gatgcctggg tctgtgagtc tgaggggagg
 aggggctggg ggccctggact cctgggtcta agtggggagg ggctggggcc aggatcttg
 15 agtctgaagg aggggggct ggggcttagg atagaaacgg tcttgtatct ggactcctgg
 ctccccaagg attgggggct ggaccaggg attactggca tattctccct tcagtgaagt
 acaacaaggg cctgacctgc tccagcatca ctatcctgag ccctaaagag tgtgagggtct
 tctaccctgg cgtggtcacc aacaacatga tatgtgctgg actggaccgg ggcaggagcc
 cttgccaggt aggtctgaa caggagagat ctctgactcc tgggaggagg gacaggagg
 20 ttatgggaaa agagcagacc ctgtgccoga tcccaaacct cattcccaa cccatccttg
 accccaactc ttaccagac ctaacccct cctcatccct atoctcaatc ccatttccat
 cctaacccea cccatttccc atctccaagc ccattttcat cccctcacct tccatgaact
 acaatcccaa cccaagtctc actgtgcctt cattctcatc cccagccca acctcccata
 acctgaagtc cacctccatt cctaccttcc agctcatacc taattccaac cccatcccat
 25 cctogtcttt atcccaaccc aacccttccc tccccacca ctgcccaga tcccaaagtg
 acagctctca cgttggcaca tttatttgat ctctcctttc tgcaccccc agagtgactc
 tggaggcccc ctggtctgtg acgagaccct ccaaggcatc ctctcgtggg gtgtttaccc
 ctgtggctct gccagcatc cagctgtcta caccagatc tgcaaatata tgcctggat
 caataaagtc atacgtcca actgatccag atgctacgct ccagctgac cagatgttat
 30 gctcctgtg atccagatgc ccagaggctc catcgtccat cctcttctc cccagtcggc
 tgaactctcc ccttgtctgc actgttcaaa cctctgccgc cctccacacc tctaaacatc
 tccctctctc cctcattccc ccacctatcc ccattctctg cctgtactga agctgaaatg
 caggaagtgg tggcaaaagt ttattccaga gaagccagga agccgggtcat caccagcct
 ctgagagcag ttactggggg caaccaacct gacttctct gccactcccc gctgtgtgac
 35 tttgggcaag ccaagtgcct tctctgaacc tcagtttcct catctgcaa atgggaacaa
 tgacgtgcct acctcttaga catgttgtga ggagactatg atataacatg tgtatgtaaa
 tcttcatgtg attgtcatgt aaggcttaac acagtgggtg gtgagttctg actaaaggtt
 acctgttctg gtgatctgac cagctcccg tgaaagcgtg tgtccaggga agaagtgcac
 agggtagccc ccaatcccaa ccttccatcc ccaaccctta gggatgatgg aaga
 40

SEQ ID NO. 11

Hk11 amino acid

45 MQRLRWLRDWKSSGRGLTAAKEPGARSSPLQAMRILQLILLALA
 TGLVGGETRIKGFECCKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIV
 HLGQHNLOKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSIWAVRP
 LTLSSRCVTAGTSCLISGWGSTSSPQLRLPHTLRANITIIHQKCNAYPGNITDTM
 50 VCAVQEGGKDSQGDGGLVLCNQLQGIISWQDPCAITRKPGVYTKVCKYVDWIQ ETMKNN

SEQ ID NO. 12

Hk11 amino acid

MRILQLILLALATGLVGGETRIKGFECCKPHSQPWQAALFEKTR
 55 LLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLOKEEGCEQTRTATESFPHPGFNNSL
 PNKDHRNDIMLVKMASPVSIWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQLRLPHT

LRCANITIIIEHQKCNAYPGNITDTMVCASVQEGGKDSQGDSSGGPLVCNQSLQGIIS
 WQDQFCAITRKPGVYTKVCKYVDWIQETMKNN

5 SEQ ID NO. 13

KLK11 nucleic acid

```

aggaaatctgc gctcgggttc cgcagatgca gaggttgagg tggtcgcgga actggaagtc 61
atcgggcaga ggtctcacag cagccaagga acctggggcc cgctcctccc ccctccaggc 121
catgaggatt ctgcagttaa tcctgcttgc tctggcaaca gggttgtag ggggagagac 181
10 caggatcatc aaggggttcg agtgcaagcc tcaactcccag ccctggcagg cagccctggt 241
cgagaagacg cggctactct gtggggcgac gctcatcgcc ccagatggc tcctgacagc 301
agcccactgc ctcaagcccc gctacatagt tcacctgggg cagcacaacc tccagaagga 361
ggagggtctgt gagcagaccc ggacagccac tgagtccttc cccacccccg gcttcaacaa 421
cagcctcccc aacaaagacc accgcaatga catcatgctg gtgaagatgg catcgccagt 481
15 ctccatcacc tgggctgtgc gacccctcac cctctcctca cgctgtgtca ctgctggcac 541
cagctgcctc atttccggct ggggcagcac gtccagcccc cagttacgcc tgcctcacac 601
cttgcgatgc gccaacatca ccatcattga gcaccagaag tgtgagaacg cctaccccg 661
caacatcaca gacaccatgg tgtgtgccag cgtgcaggaa gggggcaagg actcctgcca 721
gggtgactcc gggggccctc tgggtctgta ccagtctctt caaggcatta tctcctgggg 781
20 ccaggatccg tgtgcatca cccgaaagcc tgggtgtctac acgaaagtct gcaaatatgt 841
ggactggatc caggagacga tgaagaacaa ttagactgga cccacccacc acagcccatc 901
accctccatt tccacttggg gtttgggttc tgttactctt gtttaataaga aaccctaagc 961
caagaccctc tgcgaacatt ctttgggcct cctggactac aggagatgct gtcacttaat 1021
aatcaacctg ggggttcgaaa tcagttagac ctggattcaa attctgcctt gaaatattgt 1081
25 gactctggga atgacaacac ctggtttgtt ctctgttgta tcccagccc caaagacagc 1141
tcctggccat atatcaaggt ttcaataaat atttgctaaa tgagtg

```

SEQ ID NO. 14

KLK11 nucleic acid

30

gene 2313..7622

mRNA join(2313..2398,4189..4263,5061..5217,5545..5810,
 6627..6763,7158..7622)

35

CDS join(4224..4263,5061..5217,5545..5810,6627..6763, 7158..7310)

```

tgataaatagt gttctctctc ctcatgtggtc agggccccag ccattgtcct tgagagaatg 61
40 ctcgactctt tatgttgtct tgacagcctc ccctgagatt ggtcattaat gactgtgctc 121
tctctcctca ttggtcaggg ccccagccat tgctcctgag agaacctctg tcctttatgg 181
agttccaccc ttcttcctcg ggattggccc ctagagacag tggttcttct cttttggtta 241
gccattggca ttgtcctcgg gaaagtgat tatactcttt tgtctaata cagacttgg 301
agccctcccc aaggcccagg actgggttga aggggttggg aggaaaacag aaataagatg 361
45 tctcccttgt tcagacagta cttctcttcc cttccagggt gattctgggg gccccctggg 421
gtgtggggga gtocctcaag gtctggtgtc ctgggggtct gtggggccct gtggacaaga 481
tggcatccct ggagtctaca cctatatttg caagtatgtg gactggatcc ggatgatcat 541
gaggaacaac tgacctgtt cctccacctc cacccccacc ccttaacttg ggtaccctc 601
tggccctcag agcaccaata tctcctccat cacttccct agctccactc ttgttggcct 661
50 gggaacttct tggaacttta actcctgcca gcccttctaa gaccacagag cggggtgaga 721
gaagtgtgca atagtctgga ataaatataa atgaaggagg ggcatgtct gtccatttga 781
agtccctcat ctggttgaga ctggaagaag gactcagcag ttccctatc tcataggagt 841
agaaacagag ctcaaataag gccaggcaca gtggctcaca cctgtaatcc catcactttg 901
ggaaagctgag gcagggtgat cacctgaggt caggaactcg ggaccagcct ggtcaacata 961
55 gtgaaacccc aactctacta aaaatgcaaa aattagccag gcatggtggc gcatgcctgt 1021
aatccagct actcaggagg ctgagacagg agaatagcat gaaccctga ggcagaggct 1081
gcagcgagcc gagattgaac cattacactc cagcctgggc gacagagcga gactccatct 1141

```

	caaaaacaaa	caaacaaaa	accagtgct	caaataggat	gagggctctc	cctgagtagt	1201
	tactcagaaa	tggagtagaa	aaagtactt	ttaataatat	aggccgggtg	cagtgggcca	1261
	cgctgtaat	cccagcactt	tgaggaggcg	aggtgggagg	atggcttgag	ctcagatttc	1321
	gagatcagcc	tggcaacaca	gtgaaatctt	gtcactacaa	aaacacaaaa	aattagctgg	1381
5	gtgtgggtgt	gcgtgcctgt	agtcccagct	acttgggaag	ctgaggtggg	aggatcaccc	1441
	gagccgggga	ggtggaggct	gcaaagagcc	gagatcatgc	cactgcactc	cagcctgggc	1501
	aataaagtga	gaccttgtct	caaaaacaaa	aaccagcaa	tataaataag	acacatgttt	1561
	cttcatctgg	cataatagaa	atagtgccca	gagcttataa	gcttttcaag	agtccacaaa	1621
	agacccgaaa	aagaaaaaga	aaattgttag	ctccaaaata	ccagatgaaa	gctgcaaagt	1681
10	caacatttat	gaccatttaa	tccaatgtcc	ataaaacgta	gcattctttc	cactagccaa	1741
	ctgcagttta	ctttcttgta	atgaagcata	cattgtatct	ttaatgtggg	acgtggcttt	1801
	gttctaataa	gacgaagggt	ggagtgcagg	cttggaaagc	aggagagctc	agcctacgtc	1861
	tttaatectc	ctgcccaccc	cttggattct	gtctccactg	ggactcaaga	ggtgaggaga	1921
	gaccatctcc	ccaaatgcac	tgaagggaag	ctggaggagg	gagggagtga	gggggtatca	1981
15	taccagcgga	ggcacatttg	ctgagccccc	ccgcagctctg	ctctttccaa	gtggaccctc	2041
	ctggaagcct	gatcccaacc	tcccctgcaa	gcaggtctgt	cacccccatc	tctcagatga	2101
	agaaactgag	ccttgcaggg	gtggagtccc	ttgtccccac	gtcataaggg	tagcatagat	2161
	agtaggaaga	ggaagcacct	aggtttgagg	ccagggtctg	ctgctgtcag	aacctaggcc	2221
	ctcccctgcc	ttgctccaca	cctggctcagg	ggagagaggg	gaggaaagcc	aagggaaggg	2281
20	acctaactga	aaacaaacaa	gctgggagaa	gcaggaaatct	gcgctcgggt	tccgcagatg	2341
	cagaggttga	ggtggctgcg	ggactggaag	tcctcgggca	gaggtctcac	agcagccagt	2401
	aagtgaacag	ctggactcgg	gctgcctggg	cggcaggggag	aagcggggcag	gggaagggtc	2461
	agcagaggag	cgaggcccca	gaggagccct	gggttgaggc	acagccaagg	gctctgttcc	2521
	ctttccttga	ctcggtctcc	acaggccctg	acctgcctcc	cccaccctcc	ggtcctgccc	2581
25	ctgtgcctgg	cagcagcccc	acctgtgtga	catcccagca	cacccccctc	ctccttgcaa	2641
	aggagaaggg	agcggcctag	gggaggccag	gggcccacct	gggttggggc	tgtggagagg	2701
	gagtggctgg	gacgggagga	aaaagagaga	cggagattag	atggaagaag	agggatttca	2761
	agacaaattg	ccagagatgc	agtccagagag	actgactgag	agacacaaaag	atagaaggaa	2821
	ttagagaaaag	ggccacacag	agccagacag	agagagaaga	gtggagatgg	agacagggac	2881
30	gaggacagag	aaaggcagac	agacacatag	ggacagaaag	agaaaaatca	cacaaagtca	2941
	gaattactga	atgacaggga	atgacacata	gaacgagaca	cagattcaga	gactcagggc	3001
	agggaaagga	aggctgcaga	cagacagaca	gacagaggga	ggctgagaca	cagggagaag	3061
	aggggcttgg	agagtgggca	caggcaggca	gccagtgcct	cagaggccctc	cggggagggc	3121
	cctcacacac	accccgcctc	ggggcattaa	ggcagggtct	ggaggccagt	catcctgggc	3181
35	ccgcccaggg	ccgccccctc	gccagcccgc	ctgcctgggtg	cctggcacct	ggcgctccaa	3241
	cccagcctac	ctgctgtagc	tgccgccaact	gcccgtctccg	ccgccaactg	gccccagag	3301
	ccccagcccc	agagcctgtg	agtccaggag	gaaagggaag	ctgcccctcc	ccgtccaggt	3361
	gtcagccctc	cccaaggaca	cctgtcccac	tcgggcaccc	atttctccct	ctgctctgtc	3421
	cttctctgct	tgggtggggg	ttcctggcct	ctctctacac	ctctcacctc	cgtggtctgt	3481
40	ccgcagcctc	agttacctct	aatctccatg	gcttcagctg	ctgagctggc	cctctgtctc	3541
	cacccccgct	ggccaaggga	gcggagggca	ctggccctcc	cctcgaccag	ccccgccag	3601
	ctttgcttgg	ctgtccttca	aaagggcagg	ggtttggcgg	acagggtctc	agcaagccgg	3661
	gtgatggggg	tcccagacat	tgtctggggc	tgagccccct	actcccctcc	agcagacctc	3721
	aaaggctcca	tatcgctctg	ctgcgaagac	aatgaaaaag	gggtggctac	ggaacgggtg	3781
45	ctggttcccc	ttgtccttcc	accccaagct	gctggggcct	ggccagctct	caaggcaaga	3841
	aggaaaacat	cctctgacat	gtgccgggga	ggtcccatgg	ctgacttgaa	cagggccgaa	3901
	ccatggcttg	acagctcaaa	gccccctcca	acgacttcca	catggttctt	ggtatctcgg	3961
	aagcttctag	ctgtgaccag	gccctctcca	aggccaccct	agacacctaa	gatataat	4021
	aagtgttttg	agatctgagt	gctgtgagaa	acaggggatt	tccccaacct	tgtttctccc	4081
50	aagtggggag	cgggagcagg	tgagggagag	aggagagggc	atgagccagc	ccccccctcc	4141
	cgatttcccc	gtaaaagtgat	gcggccccat	gtccctcctt	gttccagag	gaacctgggg	4201
	cccgctcctc	ccccctccag	gccatgagga	ttctgcagtt	aatcctgctt	gctctggcaa	4261
	caggtagcga	ggggatgggg	gcagggcagg	atcctccctc	ttgaatctct	gggatccctc	4321
	aacctctctg	gtctggacag	tgacagggct	gattccaaat	tacagaacaa	cccataaggc	4381
55	acctgaactg	gagcagtggg	catgaggggc	tgtagccctt	tctagataat	ccctttaaat	4441
	gccaaaggag	gagaggtcaa	gggggtcgta	aagggtcccg	tggaggggct	gaggaaagctg	4501
	gagttggggg	agcagtcact	caaagcgccc	aggacagggg	ctactgacca	accagtatgg	4561
	aagtatttcc	tttttttttt	ttcccagaga	caaagtcttg	ctctattgtc	caggctggag	4621
	tgcctgtgtg	ccaacacggc	tcactgcagt	cttgacttcc	cgggcttaag	tgatccttaa	4681

	gccatctcag	cttccccggt	agctgggacc	acaggcacct	gccaccaagc	caggctaatt	4741
	gtttaattgt	ttgtagagat	gggggaggag	gtctcactat	gtttgcctag	gctgatctag	4801
	aactcctggg	ctcaagtaat	cctcccacct	tagcctctca	aagtgcctggg	attacaggca	4861
	tgagccactg	catttgacct	tatggaagta	ttttcatcct	ttaatacccg	accccagcat	4921
5	ccagggcaac	ccagagggac	accagaccag	ggcccagacc	acccactctc	tttctctcct	4981
	ccccacccc	atttctggga	gtcctcctgg	tctaccacct	ctccttcctg	agccccctct	5041
	tttgctctca	ccccctccag	ggcttgtagg	gggagagacc	aggatcatca	aggggttcga	5101
	gtgcaagcct	cactcccage	cctggcaggc	agccctgttc	gagaagacgc	ggctactctg	5161
	tggggcgacg	ctcatcgccc	ccagatggct	cctgacagca	gccactgcc	tcaagccgtg	5221
10	gggtgcgggg	ctggggcggt	gccggggtgg	ggggctggga	atggggagat	ggatggagag	5281
	aagctcaggg	ataggggtgc	tggttaagggg	attagagatg	gggatgggta	gtgtcagcaa	5341
	ggttgatggg	ctcgagttgg	tattgaaggt	gggggatga	atggggttgg	gatggggcta	5401
	tggctgggaa	gggggcttcg	gtgggagacg	tggaaagagt	tggaaagcaga	gcgatgtttc	5461
	ttcatctca	aaggtgtcac	tcacctctcc	cacccatgtc	tcccccgacc	tttctcctc	5521
15	caactactgt	ctctcccacc	tcagccgcta	catagttcac	ctggggcagc	acaacctcca	5581
	gaaggaggag	ggctgtgagc	agacccgac	agccactgag	tccttcccc	accccggtt	5641
	caacaacagc	ctcccccaaca	aagaccaccg	caatgacatc	atgctggtga	agatggcatc	5701
	gccagtctcc	atcacctggg	ctgtgcgacc	cctcaccctc	tcctcacgct	gtgtcactgc	5761
	tggcaccagc	tgctctcattt	ccggctgggg	cagcacgtcc	agccccaggt	gtaggagcga	5821
20	cagaggggaa	cctggcaggg	gggtgtgagg	agggagtggg	caggattgtg	gaagggttca	5881
	gggcatcaga	gatgcggttc	acagtacga	tgtgggataa	gttgagagga	tgtgtggaaa	5941
	acgtcaggat	aggggggtgg	ggacaaaagt	tggggccttg	gagtcagacg	gacgggatat	6001
	gcaatcatac	atccataacc	tcctggttgt	aagaccttag	gcaagcagct	tcacctctct	6061
	gaatcttgat	tttcttctct	ataaaatgag	aatgattata	cccactgtc	aggattggat	6121
25	tagagataat	gtatatcaag	caactgacat	aaatcattta	ttggatagca	ggctgggcac	6181
	cgtggctcac	gcctgtaatc	ccagcacttt	gggaggccga	gggtgggaaga	tcacctgagg	6241
	tcaggacttt	gataccagcc	tgccaacgt	gggtgaaatcc	catctctact	aaaaatgtga	6301
	aaattagttg	ggcgtggttg	tgtgcgcctg	taatcccagc	tactcgggag	gttgaggcag	6361
	gagaatcgct	taaaacttggg	agacggaggt	tgcagtgagc	caagatcacg	ccactgcatc	6421
30	ccagcctggg	caacagagca	agactctgtc	tcgaaaaaaa	aaaaaaaaaa	gctggatagc	6481
	attgctgttg	ctattgttac	aagaagagag	gtgagttggc	tgctgtctaa	gacagggatt	6541
	ccccaggggg	cgggatcaca	gcaagcactg	cattagggga	gggtggcagg	ggctcattcc	6601
	cacagcccct	cacgctgttt	ccacagtacg	cctgcctcac	accttgcat	gcgccaaat	6661
	caccatcatt	gagcaccaga	agtgtgagaa	cgccatcccc	ggcaacatca	cagacaccat	6721
35	gggtgtgtgc	agcgtgcagg	aagggggcaa	ggactcctgc	caggtcagtg	tggtctccaa	6781
	ccacagcccc	atccccatcc	ccagcttcaa	tgacatcttt	accgacatcc	acaatttcat	6841
	ccccaacctc	aacccgcccga	ccccgtgcaac	tcccaatcca	tctcttcccc	tggttccggt	6901
	tctgacctca	gcacaaactt	cagctccatc	cccgtttcca	caccatttcc	agctccaacc	6961
	atccccaaac	tcgttttttg	gcctaaccgc	atcctttatc	ccaccataa	tcccagcttt	7021
40	atcgctaaac	ctatcacctt	tcccagtgcc	taccatcct	gtctcggccc	cactcctaag	7081
	caccgtcccc	acctcctccc	tggttaacac	catgctcaac	gctttctctg	accgacattc	7141
	tctctccccg	tgcccagggt	gactccgggg	gccctctggt	ctgtaaccag	tctcttcaag	7201
	gcattatctc	ctggggccag	gatccgtgtg	cgatcaccog	aaagcctggt	gtctacacga	7261
	aagtctgcaa	atatgtggac	tggtatccag	agacgatgaa	gaacaattag	actggaccca	7321
45	cccaccacag	cccatcaccc	tccattttcca	cttgggtgtt	ggttccctgt	cactctgtta	7381
	ataagaaacc	ctaagccaag	accctctacg	aacattcttt	gggcctcctg	gactacagga	7441
	gatgctgtca	cttaataatc	aacctggggt	tcgaaatcag	tgagacctgg	attcaaattc	7501
	tgcttggaaa	tattgtgact	ctgggaatga	caacacctgg	ttgtgtctct	gttgtatccc	7561
	cagccccaaa	gacagctcct	ggccatata	caaggtttca	ataaatat	gctaaatgag	7621
50	tgaatctact	gagtgcttac	tatgtgctag	accctgatcc	aatggctttt	attttatttt	7681
	attttttgac	agagtctcgc	tctgtcaccc	aggctggagt	acagtgggtc	tatctctgct	7741
	cactgcaacc	tccacctcct	gggttcaagc	aattctcctg	cctcagcctc	ctgaatagct	7801
	gggattacag	gtgcctacca	ccacatccgg	ctaatttttg	tatttttttag	tagagatggg	7861
	gcttcaccat	gttggccagg	ctggtctcga	actcctgacc	tcagatgatc	tgccctcctt	7921
55	ggcctcccaa	actcctggga	ttacagacgt	gagccaccgc	gcccggcccg	ctttcattta	7981
	ttaattaaaa	gaaattaaat	taattaatct	atttaggaga	cagtcttgct	ctgtgccc	8041
	ggctggagtg	cagtaacaat	cacagctcac	ggcaatctca	atttctctgg	gtcaagtgat	8101
	tgctctccct	cagcctccag	agtagctggg	actacaggca	catgccacga	agcccagcta	8161
	atttttgtat	ttttcgtaga	gacagaggtc	tcagtatggt	gccccggcta	gtctcaaact	8221

cctgggctca agcagctctgt cctcctcagc ctccaaaagt ggtgagatta caggcatgag 8281
tcgctgtgcc tggcctccaa gcactttcaa atgtatcaac ttaatcctca caaaaccctg 8341
tgaggctcggg actgttttca tacctatatt atagttgaag aaacagacac agagaagcaa 8401
agtcacttgc tcacagtcac gtggctagga gagcaaggat ctgaagcaag gcgatctctt 8461
5 aattaccaag tgatgttcct ggagtaaggc tctgtttgtt tcctttcctg taaaatgctg 8521
catgcaaaag tataacacag taagtaaaga agtcagttag cctgcacata ctaagaccta 8581
accaaaggag cttattgttt ttctccaact tccatgatag gtaattagat agtggagacc 8641
tctgctggcc aatatggtag ccactaaccg cagctggctc ttccaattaa aattacataa 8701
agccagaaat gtaactcctc tgtctcactt gttatatctc caaggctgga tagccacatg 8761
10 tgactggtgg tggctggatt agctagtgc tataaaacat cactgcagaa agttcagctg 8821
agcagcactg agttagatgg cctctgaaga ggatgtccca cggagagaat ccagaactca 8881
ggatcttttt tttttttttt ctttgcgaca gagtcttgc ctgtcaccca ggctggagtg 8941
cagtggcgtg atctcggctc actgcaactt ctgcctccca ggttcaagca attctcctgc 9001
ctcagcctcc ctagtagctg ggactacagg cctgtgccaa catcccagc taatttttgt 9061
15 gtcttttttag tagagatggg gtttcactat gttggccagg ctggtctcga actcctgacc